ACTRIMS-ECTRIMS 2014

DISCLOSURE APPENDIX AT THE BACK OF THIS REPORT CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, AND THE STATUS OF NON-US ANALYSTS. US Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

CREDIT SUISSE SECURITIES RESEARCH & ANALYTICS BEYOND INFORMATION®

Client-Driven Solutions, Insights, and Access

03 September 2014

Americas/United States

Equity Research

Biotechnology / Major Pharmaceuticals (Biotechnology (US)/Biotechnology &

Biopharmaceuticals (Europe)) / MARKET WEIGHT

ACTRIMS-ECTRIMS 2014 COMMENT

Continuing to Monitor The Revolution

Summary: The Joint ACTRIMS-ECTRIMS (“MSBoston”) Meeting 2014 starts

this time next week (Sep 10th-13

th) in Beantown. We will be attending. This

document provides a comprehensive planner for institutional investors,

organized by: (1) Key must-attend sessions (Exhibit 1–Exhibit 5); (2) Sessions

by company (Exhibit 11 –Exhibit 21); (3) Detailed sessions by day (Exhibit 22 –

Exhibit 34); (4) Education sessions (Exhibit 6 – Exhibit 10). From a data

perspective, the key focal points are (1) RCPT's RPC1063 (RADIANCE PII

data) on Saturday, (2) ABBV's/BIIB's Zinbryta (Daclizumab) (DECIDE PIII data)

on Thursday/Friday and (3) Synthon's Generic Copaxone (GATE PIII data) on

Friday. There will be incremental data on BIIB's and GSK’s remyelination

agents. From a market dynamics perspective, the conference also will

provide granularity on (1) the continued dominance of oral agents (particularly

BIIB’s Tecfidera); (2) Earlier and "treat aggressively/earlier and to goal"

management (vs. the old paradigm of “diagnose, treat, and see”); (3) Increasing

focus on MRI in diagnosis and treatment; (4) Individualized treatment

choice/emerging treatment guidelines (5) Potential of remyelination.

■ ABBV (TP$63, OP)/BIIB (TP$425, OP) – Zinbryta (Daclizumab):

Granularity of the DECIDE PIII data on MRI data (P051, Thu), safety and

tolerability (P094, Thu), as well as primary results (FC1.1, 8:15am to 9:15am

on Fri). Recall, headline data (45% ARR, 54% T2, 16% EDSS reductions)

were announced in June.

■ BIIB (TP$425, OP) – Tecfidera: Updated five-year follow-up data for

Tecfidera on MRI data (P059, Thu) and integrated clinical efficacy (P110,

Thu) of DEFINE CONFIRM, and ENDORSE (DEFINE/CONFIRM follow-up

trial). Recall four year data were presented in March at AAN. Anti-LINGO-1:

Potential biomarkers for BIIB033 activity in PI trials (P262, Thu); Baseline

patient characteristics for RENEW PII trial in acute optic neuritis (P731, Fri).

■ RCPT (TP$58, OP) – RPC1063: Granularity of RADIANCE PII data will be

presented in an oral session (LB1.1, Sat). Recall head line data was

disclosed in early June (6m, primary MRI GdE lesion 12-24w reduction of

86%). Focus at the meeting will be on ARR and CV/LFT safety granularity.

■ GSK (1475p, UP) – GSK239512: A poster will be presented on the design

of a PIIa trial evaluating effects on lesion remyelination in RMS patients

(P726, Thu). Ofatumumab (Partnered with Genmab, Not Covered): There

will be a poster on the follow-up data from the MIRROR PII trial (P048,

Thurs). MOR103 (Partnered with Morphosys, Not Covered): The PI data

(safety and pharmacokinetics) will be presented orally (FC2.4, Fri).

(Continued on next page…)

Research Analysts

Ravi Mehrotra PhD

212 325 3487

[email protected]

Koon Ching PhD

212 325 6286

[email protected]

European Pharma Team

44 207 888 0304

[email protected]

Vamil Divan, MD

212 538 5394

[email protected]

Anuj Shah

212 325 6931

[email protected]

Ronak H. Shah, Pharm.D., CFA

212 325 9799

[email protected]

Ari Jahja

212 325 0767

[email protected]

Jason Kantor, PhD

415 249 7942

[email protected]

Jeremiah Shepard, PhD

415 249 7933

[email protected]

03 September 2014

ACTRIMS-ECTRIMS 2014 2

(Continued from previous page…)

■ Novartis (SFr90, OP) – Gilenya: Presentations correlating brain volume change to

multiple sclerosis disease-activity freedom (FC1.5, Fri) and disability progression from

FREEDOMS and extension studies (FC2.3, Fri) will be given in an oral session. A

poster on using threshold rates of brain volume loss (P290, Thurs) will be presented

too. Siponimod: There will be posters on modeling of dose-PK-lymphocyte

relationships on immune reconstitution (P050, Thu) and concentration-efficacy

relationships for MRI lesion counts (P109, Thu).

■ Sanofi (TP€80, N) – Aubagio: There will be posters on subgroup MRI data from

TOPIC (P040, Thu), pooled subgroup efficacy/safety data from TEMSO and TOWER

(P046, Thu), and pooled safety data from the clinical development program (P097,

Thu). Lemtrada: Presentations on three-year disease free outcomes data from CARE-

MS trials (FC1.4, Fri) and three-year MRI outcomes from CARE-MS I (FC2.2, Fri) will

be given in an oral session. Posters will be given on subgroup data from CARE-MS I

(P090, Thu) and CARE-MS II (P043, P044, P103, Thu).

■ Synthon (Not Covered): Generic Glatriramer Acetate: Granularity of the GATE trial

will be presented (FC1.2, Fri).

■ TEVA (Not Covered) – Copaxone TIW: The safety/tolerability data from GLACIER will

be presented orally(FC3.2, Fri). There also will be posters on comparable clinical and

MRI efficacy data (vs. Copaxone QD) (P053, Thu), convenience (P080 Thu), and

safety/tolerability data (P100, P306, Thu).

■ XNPT (TP$7, OP): Data was seen previously. A poster on PI data (blood lymphocyte

responses and pharmacokinetics) will be provided (P958, Fri).

03 September 2014


Key Sessions

Exhibit 1: Key Sessions – Wednesday, September 10, 2014 Wednesday - September 10, 2014

Time Location Type Drug Title Authors ID

08:00 - 09:30 312 Teaching Course 2: How do I

choose the correct disease-

modifying treatment?

General Choosing the right treatment for the right patient RJ Fox TC2.2




General When and how should MS treatment be switched

or escalated

BC Kieseier TC2.3

08:00 - 09:30 306 Teaching Course 7: Imaging small

parts of the nervous system

(MAGNIMS)

General Optic nerve imaging: pathophysiological insights A Toosy TC7.1

08:00 - 09:30 306 Teaching Course 7: Imaging small


(MAGNIMS)

General Deep grey matter: current and new technologies MA Rocca TC7.2

10:00 - 11:30 312 Teaching Course 9: Differential

diagnoses and diagnostic dilemmas

General Diagnostic approach to MS P Vermersch TC9.1



General Red flags in MS: zebras or horses? S Galetta TC9.2

10:00 - 11:30 311 Teaching Course 11: MRI issues in

clinical practice (MAGNIMS)

General Lesions: can we go beyond counts and volumes? N De Stefano TC11.1



General Brain atrophy: an outcome measure in clinical

studies

E Fisher TC11.2



General Imaging biomarkers of normal-appearing brain D Pelletier TC11.3

10:00 - 11:30 304 Teaching Course 13: Assessing the

drug efficacy: Challenges in study

design

General Assessing drug efficacy: challenges in study

design

F Lublin TC13.1



design

General Investigator initiated vs industry sponsored

studies, which and when - randomized trials in the

active treatment era

GR Cutter TC13.3

17:30 - 18:30 Auditorium Satellite Symposium Satellite

Symposium

Emerging Trends in MS Pathophysiology: The

Role of Mitochondria

Sanofi - - - - -


Symposium

Beyond Diagnosis: The Essential Role of MRI in

Clinical Management of Multiple Sclerosis

Biogen Idec - - - - -

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport

Multiple Companies Other

GSK Source: Company data, Credit Suisse estimates

03 September 2014


Exhibit 2: Key Sessions – Thursday, September 11, 2014 Thursday - September 11, 2014

Time Room Type Drug Title Authors ID


Symposium

Aligning Treatment Selection With Goals in

Multiple Sclerosis: How Can We Optimized

Established and Emerging Therapy in Clinical

Practice

Sanofi - - - - -

09:00 - 10:00 Auditorium Plenary Session 1 General Approaching the cause of multiple sclerosis DA Hafler PL1.1

10:30 - 12:00 Auditorium Parallel Session 1: Cell-based

Therapies

General Assessing myelin repair in multiple sclerosis: Is

imaging useful? Usable? Are we there yet?

C Laule PS1.2


Symposium

Time for change: Advancing our understanding of

MS

Novartis - - - - -

15:30 - 17:00 Hall C Poster Session 1 Aubagio MRI outcomes in patients with early multiple

sclerosis treated with teriflunomide: subgroup

analyses from the TOPIC phase 3 study

JS Wolinsky, P Truffinet, D Bauer, AE Miller, for

the Investigators of the TOPIC Study and the MRI-

AC in Houston, TX

P040

15:30 - 17:00 Hall C Poster Session 1 Plegridy Peginterferon beta-1a may improve recovery

following relapses: data from the 2-year

ADVANCE relapsing-remitting multiple sclerosis

study

BC Kieseier, TF Scott, SD Newsome, SI Sheikh,

S Hung, X You, B Sperling

P042

15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Efficacy and safety of alemtuzumab in patients

with relapsing-remitting MS who relapsed on prior

therapy: four-year follow-up of the CARE-MS II

study

H-P Hartung, DL Arnold, JA Cohen, AJ Coles, EJ

Fox, E Havrdova, KW Selmaj, DH Margolin, J

Palmer, P Oyuela, MA Panzara, DAS Compston,

on behalf of the CARE-MS II Investigators

P043

15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves quality of life in relapsing-

remitting multiple sclerosis patients who relapsed

on prior therapy: 3-year follow-up of CARE-MS II

T Moreau, DH Margolin, L Kasten, B Singer, on

behalf of the CARE-MS II Investigators

P044

15:30 - 17:00 Hall C Poster Session 1 Aubagio Evaluating the effect of teriflunomide in subgroups

defined by prior treatment: pooled analyses of the

phase 3 TEMSO and TOWER studies

MS Freedman, D Dukovic, M Benamor, P

Truffinet, L Kappos

P046

15:30 - 17:00 Hall C Poster Session 1 Siponimod Modeling dose-PK-lymphocytes relationship under

siponimod (BAF312) treatment to infer time to

immune reconstitution

C Sarr, M Savelieva, G Ette, C Petry, E

Legangneux, E Wallström

P050

15:30 - 17:00 Hall C Poster Session 1 Daclizumab Brain MRI results of DECIDE: a randomized,

double-blind trial of DAC HYP vs. IFNβ-1a in

RRMS patients

DL Arnold, L Kappos, E Havrdova, K Selmaj, A

Boyko, M Kaufman, H Wiendl, J Rose, S

Greenberg0, E Demirhan, M Sweetser, K Riester,

J Elkins

P051

15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Comparable clinical and MRI efficacy of

glatiramer acetate 40mg/mL TIW and 20mg/mL

QD: results of a systematic review and meta-

analysis

G Cutter, JS Wolinsky, G Comi, D Ladkani, V

Knappertz, A Vainstein, N Sasson, O Khan,

P053

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl

fumarate in relapsing-remitting multiple sclerosis:

MRI outcomes from DEFINE, CONFIRM, and

ENDORSE

DL Arnold, RJ Fox, R Gold, E Havrdova, L

Kappos, T Yousry, D MacManus, R Zhang, M

Yang, NC Kurukulasuriya, V Viglietta

P059

15:30 - 17:00 Hall C Poster Session 1 Laquinimod Clinical efficacy of laquinimod 0.6mg once-daily in

worsening relapsing-remitting multiple sclerosis

defined by baseline EDSS over 3

TL Vollmer, G Comi, L Kappos, X Montalban, G

Cutter, JR Steinerman, N Sasson, T Gorfine, V

Knappertz,

P062

15:30 - 17:00 Hall C Poster Session 1 Plegridy Effect of peginterferon beta-1a on MRI measures

and freedom from measured disease activity: 2-

year results from the phase 3 ADVANCE study

DL Arnold, PA Calabresi, BC Kieseier, SI Sheikh,

A Deykin, S Liu, X You, B Sperling, S Hung

P067

15:30 - 17:00 Hall C Poster Session 1 Plegridy Impact of peginterferon beta-1a treatment and

disease factors on risk of physical deterioration in

patients with multiple sclerosis: ADVANCE study

ET Kinter, S Guo, A Altincatal, I Proskorovsky, G

Phillips, B Sperling, G Sabatella

P074

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 3: Key Sessions – Thursday, September 11, 2014 Thursday - September 11, 2014


15:30 - 17:00 Hall C Poster Session 1 Plegridy Safety and tolerability of peginterferon beta-1a in

patients with relapsing-remitting multiple sclerosis:

2-year data from the ADVANCE study

BC Kieseier, PA Calabresi, Y Cui, Y Zhu, S Hung,

A Deykin, A Seddighzadeh

P085

15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Efficacy and safety of alemtuzumab in treatment-

naive patients with relapsing-remitting MS: four-

year follow-up of the CARE-MS I study

AJ Coles, DL Arnold, JA Cohen, EJ Fox, H-P

Hartung, E Havrdova, KW Selmaj, DH Margolin, J


on behalf of the CARE-MS I Investigators

P090

15:30 - 17:00 Hall C Poster Session 1 Daclizumab Safety and tolerability of daclizumab HYP

treatment in relapsing-remitting multiple sclerosis:

results of the DECIDE study

K Selmaj, L Kappos, DL Arnold, E Havrdova, A


Greenberg0, E Demirhan, K Riester, M Sweetser,

J Elkins

P094

15:30 - 17:00 Hall C Poster Session 1 Aubagio Pooled safety analyses from the teriflunomide

clinical development program

TP Leist, MS Freedman, L Kappos, TP Olsson,

AE Miller, JS Wolinsky, PW O'Connor, M

Benamor, P Truffinet, D Dukovic, G Comi0

P097

15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Indirect comparison of glatiramer acetate

40mg/mL TIW and 20mg/mL QD dosing regimen

effects on relapse rate: results of a predictive

statistical model



P100

15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves MRI outcomes in

relapsing-remitting multiple sclerosis patients who

relapsed on prior therapy: three-year follow-up of

E Fisher, F Barkhof, JA Cohen, EJ Fox, KW

Selmaj, DH Margolin, J Palmer, DL Arnold, on


P103

15:30 - 17:00 Hall C Poster Session 1 Daclizumab Integrated analysis of daclizumab HYP

pharmacokinetics from three phase 1 studies

AA Othman, JQ Tran, MT Tang, S Dutta P106

15:30 - 17:00 Hall C Poster Session 1 Siponimod Modeling concentration-efficacy relationship for

MRI lesion counts under siponimod treatment and

its dependence on the effect on lymphocyte

reduction

M Savelieva, E Wallström P109


fumarate in RRMS: integrated clinical efficacy

data from the DEFINE, CONFIRM, and

ENDORSE studies

R Gold, JT Phillips, A Bar-Or, M Hutchinson, L

Kappos, R Zhang, M Yang, NC Kurukulasuriya, V

Viglietta, RJ Fox

P110

15:30 - 17:00 Hall C Poster Session 1 BIIB033 Potential biomarkers of BIIB033 activity in phase 1

clinical studies

S Ray, J Tran, S Ciotti, Q Duong, R Huang, L

Yang, D Cadavid

P262

15:30 - 17:00 Hall C Poster Session 1 Gilenya vs.

Tecfidera

Persistence with fingolimod versus dimethyl

fumarate in patients with multiple sclerosis:

retrospective analysis of US open source

pharmacy data

N Bergvall, R Lahoz, T Nazareth, JR Korn P289

15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Reduced frequency and severity of injection site

reactions with glatiramer acetate 40mg/mL three

times weekly dosing

JS Wolinsky, Y Sidi, JR Steinerman, V Knappertz,

S Kolodny, The GLACIER Study Group

P306

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Gastrointestinal tolerability of delayed-release

dimethyl fumarate in a multicenter, open-label

study of patients with relapsing multiple sclerosis

EJ Fox, A Vasquez, W Grainger, TS Ma, C von

Hehn, J Walsh, J Li, J Zambrano

P309

15:30 - 17:00 Hall C Poster Session 1 General The changing face of MS: does ARR vary by

epoch?

BC Healy, T Chitnis, F Dangond, HL Weiner P342


Symposium

Evolving Insights Into MS Pathology: Can We

Ever Stop Disease Worsening?

Teva - - - - -

19:15 - 20:15 Small Ballroom Satellite Symposium Satellite

Symposium

Innovation and Optimization: Engaging Today's

Patients

Merck KGaA - - - - -

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 4: Key Sessions – Friday, September 12, 2014 Friday - September 12, 2014


08:15 - 09:15 Auditorium Free Communication 1 Daclizumab Primary results of DECIDE: a randomized, double-

blind, double-dummy, active-controlled trial of

daclizumab HYP vs. Interferon β-1a in RRMS

patients

L Kappos, K Selmaj, DL Arnold, E Havrdova, A



J Elkins

FC1.1

08:15 - 09:15 Auditorium Free Communication 1 Generic Copaxone Generic glatiramer acetate is equivalent to

copaxone on efficacy and safety: results of the

randomized double-blind GATE trial in multiple

sclerosis

JA Cohen, A Belova, K Selmaj, C Wolf, JJL

Oberyé, ERW van den Tweel, NP Koper, G

Voortman, F Barkhof, on behalf of the GATE

Study Group

FC1.2

08:15 - 09:15 Auditorium Free Communication 1 Alemtuzumab Disease-free outcomes with alemtuzumab: 3-year

follow-up of the CARE-MS studies

E Havrdova, DL Arnold, J Palmer, DH Margolin,

on behalf of CARE-MS I and CARE-MS II Study

Investigators

FC1.4

08:15 - 09:15 Small Ballroom

(302-304-306)

Free Communication 2 Alemtuzumab Alemtuzumab improves MRI outcomes in

treatment-naive active relapsing-remitting multiple

sclerosis patients: three-year follow-up from

CARE-MS I

DL Arnold, F Barkhof, JA Cohen, EJ Fox, KW

Selmaj, DH Margolin, J Palmer, E Fisher, on

behalf of CARE-MS I Investigators

FC2.2


(302-304-306)

Free Communication 2 Gilenya Brain volume change by quartile and disability

progression in multiple sclerosis: a 4-year analysis

of the phase 3 FREEDOMS trial and its extension

D Jeffery, E Verdun, D Piani Meier, S Ritter, P

Chin, E-W Radue, W Camu

FC2.3


(302-304-306)

Free Communication 2 MOR103 Safety and pharmacokinetics of MOR103, a

human antibody to granulocyte-macrophage

colony-stimulating factor, in patients with multiple

sclerosis

CS Constantinescu, A Asher, W Fryze, W

Kozubski, F Wagner, JJ Aram, R Tanasescu, RP

Korolkiewicz, S Steidl, T Sprenger, WE Radue

FC2.4

08:15 - 09:15 Grand Ballroom Free Communication 3 Plegridy Clinical efficacy of peginterferon beta-1a in

relapsing-remitting multiple sclerosis: 2-year data

from the phase 3 ADVANCE study

PA Calabresi, BC Kieseier, DL Arnold, L Balcer, A

Boyko, J Pelletier, S Liu, Y Zhu, SI Sheikh, A

Seddighzadeh, A Deykin, S Hung

FC2.5

08:15 - 09:15 Grand Ballroom Free Communication 3 Copaxone TIW GLACIER: open-label, randomized

safety/tolerability study of glatiramer acetate

40mg/mL three times weekly versus 20mg/mL

daily in RRMS

JS Wolinsky, DW Dietrich, TE Borresen, BF

Gilder, JR Steinerman, Y Sidi, A Vainstein, S

Kolodny, V Knappertz, GLACIER Study Group

FC3.2


(302-304-306)

Parallel Session 7: Biomarkers General Biomarkers of treatment response to MS disease

therapies

S Dhib-Jalbut PS7.2

09:45 - 11:15 Grand Ballroom Parallel Session 8: Assessing

neuroprotection

General Update on completed and ongoing

neuroprotection and repair trials

J Chataway PS8.2


Symposium

Evolving Strategies to Improve Patient-Clinician

Communication and Treatment Adherence in

Multiple Sclerosis

Teva - - - - -

14:45 - 16:15 Hall C Poster Session 2 GSK239512 The effects of GSK239512 on lesion

remyelination in a relapsing remitting MS

population: design of a phase 2a imaging study

C Schwartzbach, R Grove, P Thompson, O Graff,

MA Peykamian, K Harding, J Hilpert, R Brown, D

Arnold

P726

14:45 - 16:15 Hall C Poster Session 2 BIIB033 A phase II study of the anti-LINGO-1 monoclonal

antibody, BIIB033, in subjects with acute optic

neuritis: baseline data

D Cadavid, F Ziemssen, H Butzkueven, LJ Balcer,

SL Galetta, A Rahilly, T Dong-Si, L Xu, T

Ziemssen, RENEW Study Group

P731

14:45 - 16:15 Hall C Poster Session 2 Tysabri Correlations between patient-reported ambulatory

function (MSWS-12) and objective disability

measurements in SPMS: analysis of ASCEND

baseline data

D Mikol, MS Freedman, MD Goldman, H-P

Hartung, E Havrdova, D Jeffery, R Kapoor, A

Miller, F Sellebjerg, D Cadavid, Y Chen

P777

14:45 - 16:15 Hall C Poster Session 2 Plegridy Impact of treatment-related flu-like symptoms and

injection site reactions on quality of life in patients

with multiple sclerosis: ADVANCE study



P799

14:45 - 16:15 Hall C Poster Session 2 XP23829 Steady state pharmacokinetics and blood

lymphocyte responses in healthy subjects dosed

with XP23829, a novel fumaric acid ester for

multiple sclerosis

L Steinman, RJ Fox, D Lissin, L Clark, K Cundy P958


Symposium

Treatment Decisions at the Interactions of Trials

and Practice

Biogen idec - - - - -

18:30 - 19:30 Small Ballroom Satellite Symposium Satellite

Symposium

Treating to target and beyond: Is improvement in

functioning a realistic treatment goal in multiple

sclerosis?

AbbVie - - - - -

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 5: Key Sessions – Saturday, September 13, 2014 Saturday - September 13, 2014

Time Room Type Title Authors ID


(302-304-306)

Industry Support Satellite Symposia Satellite

Symposium

Shifting the Paradigm in Multiple Sclerosis

Treatment by Targeting New Pathways

Roche - - - - -

08:30 - 10:00 Auditorium Late Breaking News RPC1063 Phase 2 results of the RADIANCE trial: a

randomized, double-blind, placebo-controlled trial

of oral RPC1063 in relapsing multiple sclerosis

J Cohen, DL Arnold, G Comi, A Bar-Or, S

Gujrathi, JP Hartung, A Olson, M Cravets, PA

Frohna, K Selmaj

LB1.1

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Sessions by Company/Type

Exhibit 6: General/Satellite Symposium Sessions General

Key? Time Location Type Drug Title Authors ID

08:00 - 09:30

Wed - 9/10

304 Teaching Course 1: Current

controversy in management:

Interactive case discussion

General Current controversy in management: interactive

case discussion

AE Miller TC1.1

08:00 - 09:30

Wed - 9/10

312 Teaching Course 2: How do I



General Treating CIS and early RRMS: pros and cons A Goodyear TC2.1

●08:00 - 09:30

Wed - 9/10





●08:00 - 09:30

Wed - 9/10





or escalated

BC Kieseier TC2.3

08:00 - 09:30

Wed - 9/10

310 Teaching Course 3: Symptom

management

General Symptom management - focus on gait impairment A Goodman TC3.1

08:00 - 09:30

Wed - 9/10


management

General Effective management of spasticity AJ Thompson TC3.2

08:00 - 09:30

Wed - 9/10


management

General Exercise therapy as symptomatic treatment U Dalgas TC3.3

08:00 - 09:30

Wed - 9/10

313 Teaching Course 5: Clinically

isolated syndromes (CIS)

General Radiologically isolated syndrome: pre-

symptomatic MS?

DT Okuda TC5.1

08:00 - 09:30

Wed - 9/10

313 Teaching Course 5: Clinically


General How can we treat and manage CIS patients? M Tintore TC5.3

●08:00 - 09:30

Wed - 9/10

306 Teaching Course 7: Imaging small


(MAGNIMS)


●08:00 - 09:30

Wed - 9/10

306 Teaching Course 7: Imaging small


(MAGNIMS)


10:00 - 11:30

Wed - 9/10

310 Teaching Course 8: Update in

pediatric MS

General Diagnosis of MS and acute demyelinating

disorders in children

C Hemingway TC8.1

10:00 - 11:30

Wed - 9/10


pediatric MS

General Emerging therapies and clinical trials in pediatric

MS

T Chitnis TC8.2

10:00 - 11:30

Wed - 9/10


pediatric MS

General MRI: role in assessment of MS disease activity

and disease impact in patients with MS onset

during childhood

BL Banwell TC8.3

●10:00 - 11:30

Wed - 9/10

312 Teaching Course 9: Differential



LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




●10:00 - 11:30

Wed - 9/10




10:00 - 11:30

Wed - 9/10



General MS differential diagnoses E Waubant TC9.3

10:00 - 11:30

Wed - 9/10

302 Teaching Course 10:

Neuroimmunology in relation to MS

pathophysiology and

immunotherapy

General Inadequate activation of T cells in MS: possible

mechanisms involved

RS LIBLAU TC10.1

10:00 - 11:30

Wed - 9/10



pathophysiology and

immunotherapy

General Contribution of B cell: T cell interactions to CNS

inflammation in MS

A Bar-Or TC10.2

10:00 - 11:30

Wed - 9/10



pathophysiology and

immunotherapy

General Immune cell trafficking to the CNS, mechanisms

and therapeutic implications

MH Han TC10.3

●10:00 - 11:30

Wed - 9/10

311 Teaching Course 11: MRI issues in



●10:00 - 11:30

Wed - 9/10




studies

E Fisher TC11.2

●10:00 - 11:30

Wed - 9/10




10:00 - 11:30

Wed - 9/10

313 Teaching Course 12: Neuro-

opthalmology update

General Visual manifestations of CNS demyelinating

disorders

FE Costello TC12.1

10:00 - 11:30

Wed - 9/10

313 Teaching Course 12: Neuro-

opthalmology update

General The role of visual outcomes in MS clinical trials LJ Balcer TC12.3

●10:00 - 11:30

Wed - 9/10

304 Teaching Course 13: Assessing the


design


design

F Lublin TC13.1

10:00 - 11:30

Wed - 9/10



design

General Assessing treatment efficacy in MS: observational

studies vs clinical trials

MP Sormani TC13.2

●10:00 - 11:30

Wed - 9/10



design




GR Cutter TC13.3

10:00 - 11:30

Wed - 9/10


Neuropsychiatric manifestations and

cognitive impairment

General The manifestations of cognitive and psychiatric

disorders in MS and assessment strategies

R Benedict TC14.1

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014



Key? Time Room Type Drug Title Authors ID

10:00 - 11:30

Wed - 9/10




General Treatment of disorders of mood and affect in MS

patients

A Feinstein TC14.2

10:00 - 11:30

Wed - 9/10




General Treatment of cognitive dysfunction in MS patients MP Amato TC14.3

●17:30 - 18:30

Wed - 9/10

Auditorium Satellite Symposium Satellite

Symposium



Sanofi - - - - -

●18:45 - 19:45

Wed - 9/10


Symposium




●

07:15 - 08:15

Thus - 9/11


Symposium




Practice

Sanofi - - - - -

●10:00 - 11:30

Thu - 9/11

Auditorium Plenary Session 1 General Approaching the cause of multiple sclerosis DA Hafler PL1.1

●10:00 - 11:30

Thu - 9/11

Auditorium Parallel Session 1: Cell-based

Therapies



C Laule PS1.2

10:00 - 11:30

Thu - 9/11

Small Ballroom

(302-304-306)

Parallel Session 4: EAE and other

animal models

General What can EAE teach us about MS? JM Goverman, MC Johnson, ER Pierson, SB

Simmons

PS4.1

10:00 - 11:30

Thu - 9/11

Auditorium Parallel Session 6: Risk

management with MS Therapy

General PML with novel immunotherapies: Is there light at

the end of the tunnel?

R Gold PS6.1

●12:30 - 13:30 Auditorium Satellite Symposium Satellite

Symposium


MS

Novartis - - - - -

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 General Time to relapse among propensity score matched

patients receiving disease modifying therapy for

multiple sclerosis

BH Johnson, MM Bonafede, C Watson P304

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 General Real-world titration of disease modifying therapies

in the treatment of multiple sclerosis: findings

from a survey of neurologists

T Nazareth, J Marvel, S Sikirica, J Xie, W

Reichmann, C Zhao, R Sasane

P307

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 General The changing face of MS: does ARR vary by

epoch?


15:30 - 17:00

Thu - 9/11

Auditorium Hot Topic 2: New routes of drug

development

General Repurposing drugs for disease modification in

multiple sclerosis

K Schmierer HT2.1

15:30 - 17:00

Thu - 9/11


development

General A perspective on generic medications to treat MS JA Cohen HT2.2

15:30 - 17:00

Thu - 9/11


development

General From genetic findings to drug discovery: taking

the first step

NA Patsopoulos, JM Replogle, HT2.3

15:30 - 17:00

Thu - 9/11

Small Ballroom

(302-304-306)

Hot Topic 3: Symptomatic and

rehabilitation strategies

General Cognitive impairment MP Amato HT3.1

●18:00 - 19:00

Thus - 9/11


Symposium



Teva - - - - -

●19:15 - 20:15

Thus - 9/11

Small Ballroom Satellite Symposium Satellite

Symposium


Patients


●17:00 - 17:45

Fri - 9/12

Small Ballroom

(302-304-306)


therapies

S Dhib-Jalbut PS7.2

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




17:00 - 17:45

Fri - 9/12

Small Ballroom

(302-304-306)

Parallel Session 7: Biomarkers General Immunological biomarkers that identify MS

patients with high probability of being free of

disease activity if treated with IFN-beta

JC Alvarez-Cermeño, R Alenda, L Costa-

Frossard, R Alvarez-Lafuente, C Picon, M Espiño,

E Roldan, R Arroyo, E Rodriguez-Martin, LM Villar

PS7.3

17:00 - 17:45

Fri - 9/12

Grand Ballroom Parallel Session 8: Assessing

neuroprotection

General Pathways to neurodegeneration: insights from

imaging in MS and other neurodegenerative

disorders

M Inglese PS8.1

●08:15 - 09:15

Fri - 9/12

Grand Ballroom Parallel Session 8: Assessing

neuroprotection



J Chataway PS8.2

08:15 - 09:15

Fri - 9/12

Auditorium Parallel Session 9: Treatment

strategies in clinical practice

General Differentiation and quantification of inflammation,

demyelination, and axon injury in human multiple

sclerosis using diffusion basis spectrum imaging

Y Wang, P Sun, Q Wang, C-W Chiang, RE

Schmidt, RT Naismith, AH Cross, S-K Song

PS8.6

08:15 - 09:15

Fri - 9/12



General Is no evidence of disease activity a realistic

treatment target?

H-P Hartung PS9.1

08:15 - 09:15

Fri - 9/12



General Treatment algorithms in patients with ongoing

disease activity

X Montalban PS9.2

08:15 - 09:15

Fri - 9/12

Grand Ballroom Parallel Session 11: Gray matter

pathology and mechanisms of

progression

General Demyelinating lesions in multiple sclerosis:

experimental evidence indicating why, how and

where they may form

RA Desai, AL Davies, M Kasti, F Laulund, KJ

Smith

PS10.3

08:15 - 09:15

Fri - 9/12

Auditorium Parallel Session 12: Study design

and endpoints

General Is primary progressive MS a distinct disease? S Vukusic PS11.2

08:15 - 09:15

Fri - 9/12

Auditorium Parallel Session 12: Study design

and endpoints

General Pragmatic clinical trials and observational studies M Trojano PS12.2

08:15 - 09:15

Fri - 9/12

Small Ballroom

(302-304-306)

Hot Topic 4: Remyelination General Defining brain volume cut-offs to predict disability

progression in MS: an analysis of a large cohort of

relapsing-remitting MS patients

MP Sormani, L Kappos, EW Radue, J Cohen, F

Barkhof, T Sprenger, D Piani Meier, D Häring, D

Tomic, N De Stefano

PS12.3

08:15 - 09:15

Fri - 9/12

Hall C Poster Session 2 General Histamine H3 receptor negatively regulates

oligodendrocyte differentiation and myelination

RR Wang, Y Chen, T Guo, W Zhen, TB Guo, RY

Zhao, AA Liu, JP Rubio, D Krull, J Lu, M Song, P

Thompson, S Wang, JC Richardson

P621

09:45 - 11:15

Fri - 9/12

Hall C Poster Session 2 General Optic neuritis associated with multiple sclerosis:

VEPs sensitive in acute phase, OCT useful in

chronic phase

G Di Maggio, RI Santangelo, S Guerrieri, L

Ferrari, S Medaglini, M Rodegher, B Colombo, L

Moiola, U Del Carro, V Martinelli, G Comi, L

Leocani

P676

09:45 - 11:15

Fri - 9/12

Hall C Poster Session 2 General Visual evoked potentials and optic coherence

tomography in monitoring involvement of visual

pathways in multiple sclerosis

L Leocani, S Guerrieri, G Di Maggio, R

Santangelo, L Ferrari, S Medaglini, M Rodegher,

B Colombo, L Moiola, U Del Carro, V Martinelli, G

Comi

P704

09:45 - 11:15

Fri - 9/12

Hall C Poster Session 2 General Small molecule inducers of oligodendrocyte

differentiation

B Bai, R Avila, M Torres-Castillo, S Lunn, S

Medicetty, B Trapp

P721

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




09:45 - 11:15

Fri - 9/12

Hall C Poster Session 2 General A high throughput flow cytometry based approach

to assess the differentiation of oligodendrocyte

precursor cells into mature oligodendrocytes

C Hollins, H Sandig, C Glover, C Jones, M

Sleeman

P728

●12:00 - 13:00

Fri - 9/12


Symposium



Multiple Sclerosis

Teva - - - - -

13:15 - 14:45

Fri - 9/12

Hall C Poster Session 2 General Clinical and molecular markers that predict

severity of relapsing-remitting MS (RRMS)

disease outcomes

J Goyal, J Bienkowska, R Hosur, M Yang, S

Feng, V Viglietta, D Mikol

P761

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 General Identifying an important change threshold for the

Multiple Sclerosis Walking Scale-12 (MSWS-12)

L Mehta, M McNeill, J Hobart, K Wyrwich, JL

Poon, P Auguste, ZJ Zhong, J Elkins

P783

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 General Psychometric testing of the early mobility

impairment questionnaire for multiple sclerosis

T Ziemssen, A Mathias, C Coon, S Agarwal, R

Shah, G Phillips

P784

14:45 - 16:15

Fri - 9/12

Small Ballroom

(302-304-306)

Hot Topic 4: Remyelination General Epigenome-wide studies: what can we learn from

them?

P Casaccia HT4.1

14:45 - 16:15

Fri - 9/12

Small Ballroom

(302-304-306)

Hot Topic 4: Remyelination General Remyelination in the adult central nervous

system: mechanisms and perspectives

C Lubetzki HT4.2

14:45 - 16:15

Fri - 9/12

Grand Ballroom Hot Topic 5: Inflammation and

neurodegeneration

General Fluorosamine that targets scar components is a

novel therapeutic that promotes myelin

regeneration and reduces inflammation in

demyelination models

M Keough, J Rogers, P Zhang, S Jensen, E

Stephenson, J Plemel, M Hurlbert, C-C Ling, VW

Yong

HT4.3

14:45 - 16:15

Fri - 9/12

Auditorium Hot Topic 6: Society and MS General Neuro-axonal damage in MS may be mediated by

interaction of innate immunity and anti-axonal

antibodies

JD Black, MS Freedman HT5.3

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 General Patients as partners in clinical research - Does

the Internet harm or help?

P Wicks HT6.2

●17:15 - 18:15

Fri - 9/12


Symposium


and Practice


●18:30 - 19:30

Fri - 9/12

Small Ballroom Satellite Symposium Satellite

Symposium



sclerosis?

AbbVie - - - - -

●07:15 - 08:15

Sat - 9/13

Small Ballroom

(302-304-306)


Symposium



Roche - - - - -

14:45 - 16:15

Sat - 9/13

Auditorium Late Breaking News General The Genomic map of multiple sclerosis: over 45

novel susceptibility variants and translation of

genetics to biology

P De Jager, International MS Genetics

Consortium

LB1.4

14:45 - 16:15

Sat - 9/13

Auditorium Plenary Session 2 General ACTRIMS-ECTRIMS Clinical Research Highlights Speaker: Ellen Mowry PL2.2

14:45 - 16:15

Sat - 9/13

Auditorium Plenary Session 2 General ACTRIMS-ECTRIMS Basic Research Highlights Speaker: Finn Sellebjerg PL2.3

16:15 - 17:00

Sat - 9/13

Outside Hall C Late Breaking News Posters General Oligodendroglial cells and signs of remyelination

are present in a subset of early active and inactive

MS lesions despite pronounced axonal damage

E Bahn, C Theodossiou-Wegner, W Brück LBP9

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 11: Acorda Acorda


10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Ampyra Treatment patterns and budget impact of

dalfampridine in multiple sclerosis: a retrospective

claims database analysis

S Palli, M Sidovar, M Grabner, A Guo P010

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Ampyra Evaluation of patient health status in the PR-

fampridine ENABLE study using SF-36-derived

utility scores

A Lee, P Wang, M Yeh P785

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Ampyra Walking ability and balance in patients with

multiple sclerosis treated with prolonged-release

fampridine: randomized, double-blind MOBILE

study

R Hupperts, J Lycke, C Short, C Gasperini, M

McNeill, R Medori, L Mehta, J Elkins

P922

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Ampyra Safety, quality of life, and walking ability with PR-

fampridine treatment in clinical practice in France:

interim results of the LIBERATE study

J-P Neau, G Castelnovo, T Soisson, A

Kwiatkowski, M McNeill, M Yeh

P924

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



Exhibit 12: Bayer Bayer


15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Betaseron Interferon beta-1b in treatment-naïve paediatric

patients with relapsing-remitting MS: baseline

data from the BETAPAEDIC study

J Gärtner, W Brück, A Weddige, K Reinhardt, JP

Bugge, The BETAPAEDIC Study Group

P089

14:45 - 16:15

Sat - 9/13

Outside Hall C Late Breaking News Posters Betaseron Clinical outcomes in patients with CIS treated with

interferon beta-1b: 11-year follow-up of BENEFIT

L Kappos, G Edan, MS Freedman, X Montalbán,

DH Miller, H-P Hartung, B Hemmer, EJ Fox, F

Barkhof, S Schippling0, A Schulze, D Pleimes, C

Pohl, R Sandbrink, G Suarez, E-M Wicklein, on

behalf of the BENEFIT Study Group

LBP17

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 13: Biogen Idec Biogen Idec


●10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Plegridy Peginterferon beta-1a may improve recovery



study



P042

●

10:30 - 12:00

Thu - 9/11

Hall C Poster Session 1 Daclizumab Brain MRI results of DECIDE: a randomized,


RRMS patients




J Elkins

P051

10:30 - 12:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Effect of bismuth subsalicylate on gastrointestinal

events associated with delayed-release dimethyl

fumarate: a double-blind, placebo-controlled study

C Tornatore, J Li, TS Ma, C von Hehn, J Walsh, J

Zambrano

P052

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Delayed-release dimethyl fumarate and disability

assessed by the multiple sclerosis functional

composite: integrated analysis of DEFINE and

CONFIRM

G Giovannoni, R Gold, L Kappos, DL Arnold, A

Bar-Or, NC Kurukulasuriya, M Yang, SP Sarda

P057

●

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl



ENDORSE




P059

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Long-term efficacy of delayed-release dimethyl

fumarate in newly diagnosed patients with RRMS:

an integrated analysis of DEFINE, CONFIRM, and

ENDORSE

R Gold, G Giovannoni, JT Phillips, RJ Fox, A

Zhang, NC Kurukulasuriya

P064

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Efficacy of delayed-release dimethyl fumarate for

RRMS in prior interferon users in the DEFINE and

CONFIRM studies

Ó Fernández, G Giovannoni, RJ Fox, R Gold, JT

Phillips, M Okwuokenye, A Zhang, NC

Kurukulasuriya

P065

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Long-term follow-up of the safety of delayed-

release dimethyl fumarate in RRMS: interim

results from the ENDORSE extension study

C Pozzilli, JT Phillips, RJ Fox, K Selmaj, R Zhang,

M Novas, MT Sweetser, R Gold

P066

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Plegridy Effect of peginterferon beta-1a on MRI measures





P067

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tysabri Quantifying the effect of natalizumab on the total

disability burden of MS patients in AFFIRM using

an exploratory area under the curve analysis

RA Rudick, S Shang, Q Dong, D Paes, D Mikol, S

Belachew

P073

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Plegridy Impact of peginterferon beta-1a treatment and





P074

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Lymphocyte count reductions with delayed-

release dimethyl fumarate: integrated analysis of

the phase 2, phase 3, and extension studies

RJ Fox, A Chan, R Gold, JT Phillips, K Selmaj, R

Zhang, H Yuan, M Novas, V Viglietta, NC

Kurukulasuriya

P077

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Plegridy Safety and tolerability of peginterferon beta-1a in





P085

●

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Daclizumab Safety and tolerability of daclizumab HYP






J Elkins

P094

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Differential recovery from relapse between

treatment groups in the CONFIRM study of

delayed-release dimethyl fumarate

A Chan, JT Phillips, RJ Fox, A Zhang, M

Okwuokenye, NC Kurukulasuriya

P096

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 14: Biogen Idec Biogen Idec


●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Daclizumab Integrated analysis of daclizumab HYP



15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Efficacy of delayed-release dimethyl fumarate in

multiple sclerosis patients with moderate

disability: an integrated analysis of the phase 3

studies

M Hutchinson, A Zhang, M Yang, M Okwuokenye,

NC Kurukulasuriya, RJ Fox, R Gold

P108

●

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl



ENDORSE studies



Viglietta, RJ Fox

P110

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tysabri Natalizumab decreases progression of disability in

RRMS patients as measured by the composite

EDSS-Plus in AFFIRM

Q Dong, RA Rudick, D Paes, D Mikol, S Belachew P113

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 BIIB033 Potential biomarkers of BIIB033 activity in phase 1

clinical studies


Yang, D Cadavid

P262

● Thu - 9/11 Hall C Poster Session 1 Tecfidera Gastrointestinal tolerability of delayed-release





P309

●

15:30 - 17:00

Fri - 9/12

Auditorium Free Communication 1 Daclizumab Primary results of DECIDE: a randomized, double-



patients




J Elkins

FC1.1

●15:30 - 17:00

Fri - 9/12

Grand Ballroom Free Communication 3 Plegridy Clinical efficacy of peginterferon beta-1a in






FC2.5

17:00 - 17:45

Fri - 9/12

Small Ballroom

(302-304-306)

Parallel Session 7: Biomarkers Tecfidera Long-term follow-up of the effect of delayed-

release dimethyl fumarate on no evident disease

activity in patients with multiple sclerosis

G Giovannoni, R Gold, RJ Fox, L Kappos, T

Phillips, A Zhang, NC Kurukulasuriya, E Havrdova

FC3.5

●13:15 - 14:45

Fri - 9/12

Hall C Poster Session 2 BIIB033 A phase II study of the anti-LINGO-1 monoclonal






P731

●14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Tysabri Correlations between patient-reported ambulatory



baseline data




P777

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Tecfidera An interim analysis of quality of life in patients with

relapsing-remitting multiple sclerosis treated with


M Kita, RJ Fox, R Gold, G Giovannoni, T Phillips,

SP Sarda, M Okwuokenye, J Kong, R Zhang, NC

Kurukulasuriya, L Kappos

P790

●14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Plegridy Impact of treatment-related flu-like symptoms and





P799

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Tecfidera Delayed-release dimethyl fumarate and

pregnancy: preclinical studies and pregnancy

outcomes from clinical trials and postmarketing

experience

R Gold, JT Phillips, E Havrdova, A Bar-Or, L

Kappos, H Yuan, P Valencia, L Oliva, M Novas, J

Li, MT Sweetser, NC Kurukulasuriya, V Viglietta,

RJ Fox

P839

14:45 - 16:15

Sat - 9/13

Outside Hall C Late Breaking News Posters Tecfidera DMF protects neural stem/progenitor cells and

differentiated neurons from oxidative damage

through regulating anti-oxidative stress genes

S Chuikov, S Taitano, Q Wu, Y Mao-Draayer LBP14

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 15: GSK GSK


10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Ofatumumab Follow-up data from the Mirror study: a dose-

ranging study of subcutaneous ofatumumab in

subjects with relapsing-remitting multiple sclerosis

PS Sorenson, ST Kavanagh, DJ Austin, RA

Grove, MC Lopez, JM Tolson, SA Van Meter, A

Bar-Or

P048

●15:30 - 17:00

Fri - 9/12

Small Ballroom

(302-304-306)




sclerosis




FC2.4

●09:45 - 11:15

Fri - 9/12

Hall C Poster Session 2 GSK239512 The effects of GSK239512 on lesion





Arnold

P726

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 16: Novartis Novartis


10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Gilenya The effects of age and gender on brain volume in

FREEDOMS, FREEDOMS II and TRANSFORMS

phase 3 studies

E-W Radue, JS Wolinsky, D Tomic, DA Häring, P

Chin, F Barkhof

P047

●09:00 - 10:00

Thu - 9/11

Hall C Poster Session 1 Siponimod Modeling dose-PK-lymphocytes relationship under





P050

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya Time to brain atrophy is prolonged in continuously

fingolimod-treated MS patients vs placebo or

interferon beta 1-a in phase 3 studies of

fingolimod

D Häring, D Tomic, D Piani Meier, N Sfikas, P

Chin, G Francis

P081

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya Safety and tolerability of fingolimod in relapsing-

remitting multiple sclerosis: results from a large

open-label clinical trial

A Laroni, D Brogi, V Brescia Morra, L Guidi, C

Pozzilli, G Comi, A Lugaresi, R Turrini, D

Raimondi, A Uccelli, GL Mancardi, EAP

Investigators

P083

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya An interim analysis of the German START-study

confirms the good cardiac safety profile of

fingolimod

V Limmroth, S Hoyer, M Lang, S Schmidt, T

Ziemssen

P086

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya Effect of fingolimod on evolution of baseline

enhancing MRI lesions into persistent T1

hypointense lesions: post hoc analysis of the

FREEDOMS study

EW Radue, T Sprenger, A de Vera, G Francis, E

Rochotte, D Tomic, L Kappos

P101

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya 24 month PANGAEA: a 5-year non-interventional

study of safety, efficacy and pharmacoeconomic

data for fingolimod patients in daily clinical

T Ziemssen, A Fuchs, H-J Schwarz, T van

Lokven, C Cornelissen

P107

●

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Siponimod Modeling concentration-efficacy relationship for



reduction


15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya Impact of fingolimod on achieving no evidence of

disease activity in pre-treated patients with high

disease activity in FREEDOMS and FREEDOMS

II

N Bergvall, D Tomic, N Sfikas, L Kappos P112

●

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya vs.

Tecfidera




pharmacy data


15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya Including threshold rates of brain volume loss in

the definition of disease-activity-free in multiple

sclerosis using fingolimod phase 3 data

N De Stefano, T Sprenger, MS Freedman, B

Cree, MP Sormani, DA Häring, G Francis, D Piani

Meier, D Tomic, L Kappos

P290

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Tecfidera vs.

Gilenya

Comparative tolerability and efficacy of dimethyl

fumarate and fingolimod in multiple sclerosis

S Cohn, R Bermel, C Hara, C Hersh, RJ Fox, J

Cohen, D Ontaneda

P300

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Gilenya Sustained low rate of brain volume loss under

long-term fingolimod treatment in relapsing

multiple sclerosis: results from the LONGTERMS

study

EW Radue, F Barkhof, J Cohen, R Gottschalk, Y

Zhang, L Cappiello, P von Rosenstiel, L Kappos

P439

08:15 - 09:15

Fri - 9/12

Small Ballroom

(302-304-306)

Free Communication 2 Gilenya Inclusion of brain volume loss in a revised

measure of multiple sclerosis disease-activity

freedom: the effect of fingolimod

L Kappos, E-W Radue, MS Freedman, B Cree,

MP Sormani, N Sfikas, G Francis, D Tomic, D

Piani Meier, N De Stefano

FC1.5

●15:30 - 17:00

Fri - 9/12

Small Ballroom

(302-304-306)






FC2.3

08:15 - 09:15

Fri - 9/12

Hall C Poster Session 2 Gilenya Identification of tissue-specific MRI markers to

assess protection and repair in response to

fingolimod

C Berrios-Otero, L Fleysher, J Zhang, E

Fieremans, G John, M Inglese

P497

08:15 - 09:15

Fri - 9/12

Hall C Poster Session 2 M356 Comparative efficacy between a generic (M356)

and brand Copaxone® (glatiramer acetate

injection) in an animal model of multiple sclerosis

C Honan, TC Ganguly, I Fier, GV Kaundinya P600

14:45 - 16:15

Sat - 9/13

Outside Hall C Late Breaking News Posters Siponomid Impact of siponimod (BAF 312) on CNS

remyelination in a transgenic Xenopus model

A Mannioui, L Azoyan, D Du Pasquier, B Zalc LBP6

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 17: Sanofi Sanofi


10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Lemtrada Cost-effectiveness of alemtuzumab vs

subcutaneous interferon beta-1a for treatment of

active relapsing-remitting multiple sclerosis: payer

perspective

C Celestin, GR Cutter, AJ Coles, A Reimers, DH

Margolin, on behalf of the CARE-MS I and II

Investigators

P013

●10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Aubagio MRI outcomes in patients with early multiple





AC in Houston, TX

P040

●10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Lemtrada Efficacy and safety of alemtuzumab in patients



study





P043

●10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Lemtrada Alemtuzumab improves quality of life in relapsing-





P044

●10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Aubagio Evaluating the effect of teriflunomide in subgroups




Truffinet, L Kappos

P046

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Aubagio The efficacy of teriflunomide is evident before

steady-state plasma concentrations are reached

JS Wolinsky, D Dukovic, P Truffinet, L Kappos,

for the investigators of the Phase Proof-of-

Concept, TEMSO, TOWER and TOPIC Studies,

and the MRI-AC in Houston, TX

P058

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Aubagio Effect of teriflunomide on lymphocyte and

neutrophil counts: pooled analyses from four

placebo-controlled studies

G Comi, MS Freedman, L Kappos, AE Miller, TP

Olsson, JS Wolinsky, M Benamor, D Dukovic, P

Truffinet, PW O'Connor

P060

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Lemtrada Alemtuzumab improves MRI outcomes regardless

of subgroup versus interferon beta-1a in relapsing-

remitting MS patients who relapsed on prior

therapy

F Barkhof, E Fisher, J Palmer, DH Margolin, DL

Arnold, on behalf of the CARE-MS II Investigators

P075

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Aubagio Long-term MRI outcomes from patients treated

with teriflunomide: results from a phase 2

extension study

DBK Li, AL Traboulsee, P Truffinet, D Dukovic,

PW O’Connor

P079

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Lemtrada Alemtuzumab reduces disease activity in

treatment-naive patients with highly active

relapsing-remitting multiple sclerosis

S Krieger, C Lubetzki, J Palmer, DH Margolin, on

behalf of CARE-MS I Study Investigators

P088

●

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Lemtrada Efficacy and safety of alemtuzumab in treatment-







P090

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Aubagio Efficacy of teriflunomide in patients with early

stage MS: analysis of the TOPIC study using

2010 McDonald diagnostic criteria



AC in Houston, TX

P095

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Aubagio Pooled safety analyses from the teriflunomide





P097

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Lemtrada Alemtuzumab improves MRI outcomes in






P103

●08:15 - 09:15

Fri - 9/12

Auditorium Free Communication 1 Lemtrada Disease-free outcomes with alemtuzumab: 3-year




Investigators

FC1.4

●15:30 - 17:00

Fri - 9/12

Small Ballroom

(302-304-306)

Free Communication 2 Lemtrada Alemtuzumab improves MRI outcomes in



CARE-MS I




FC2.2

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Lemtrada Defining clinical meaning of patient-reported

outcomes with disability assessment in multiple

sclerosis: an analysis of the CARE-MS II study

L Steinman, H Wang, Y Liu, J Palmer, Q Zhang,


P802

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 Lemtrada Pregnancy outcomes in the alemtuzumab MS


P McCombe, A Achiron, DH Margolin, J Palmer, P

Oyuela, on behalf of the CAMMS, CARE-MS I,

and CARE-MS II Investigators

P842

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 18: Teva Teva


10:00 - 11:30

Thu - 9/11

Hall C Poster Session 1 Laquinimod Effect of laquinimod on gray matter and white

matter atrophy in relapsing-remitting multiple

sclerosis: analysis of the BRAVO phase III trial

K Nakamura, TL Vollmer, T Gorfine, V Knappertz,

DL Arnold

P041

●14:00 - 15:30

Thu - 9/11

Hall C Poster Session 1 Copaxone TIW Comparable clinical and MRI efficacy of



analysis



P053

14:00 - 15:30

Thu - 9/11

Hall C Poster Session 1 Laquinimod Switching from interferon β-1a IM to laquinimod:

safety and efficacy results from the BRAVO study

extension

TL Vollmer, N Ashtamker, Y Sidi, D Ladkani, T

Gorfine, PS Sørensen

P054

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Laquinimod Consistent effect of laquinimod on relapse-related

and disability progression-related endpoints

G Comi, TL Vollmer, L Kappos, X Montalban, T

Gorfine, N Sasson, V Knappertz,

P061

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Laquinimod Clinical efficacy of laquinimod 0.6mg once-daily in





Knappertz,

P062

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Laquinimod Laquinimod effect on confirmed disability

progression: minimal mediation by relapse or T2

lesions reduction

MP Sormani, TL Vollmer, G Comi, Y Sidi, JR

Steinerman, T Gorfine, V Knappertz,

P069

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Laquinimod Laquinimod disability progression effects are

maintained with increasingly rigorous confirmation

time intervals

G Comi, TL Vollmer, L Kappos, X Montalban, N

Sasson, T Gorfine, V Knappertz,

P070

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Laquinimod Temporal pattern of laboratory changes with

laquinimod treatment

TL Vollmer, G Comi, PS Sørensen, N Sasson, T

Gorfine, V Knappertz,

P071

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Copaxone TIW Convenience of glatiramer acetate 40mg/mL three

times weekly: evidence from the GLACIER study

JS Wolinsky, TE Borresen, DW Dietrich, BF

Gilder, Y Sidi, JR Steinerman, V Knappertz, S

Kolodny, GLACIER Study Group

P080

●

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Copaxone TIW Indirect comparison of glatiramer acetate



statistical model



P100

●15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Copaxone TIW Reduced frequency and severity of injection site


times weekly dosing



P306

●

15:30 - 17:00

Fri - 9/12

Auditorium Free Communication 1 Generic Copaxone Generic glatiramer acetate is equivalent to



sclerosis




Study Group

FC1.2

08:15 - 09:15

Fri - 9/12

Auditorium Free Communication 1 Laquinimod Long-term follow-up of laquinimod in patients with


G Comi, TL Vollmer, N Ashtamker, Y Sidi, D

Ladkani, T Gorfine, PS Sørensen

FC1.3

●15:30 - 17:00

Fri - 9/12

Grand Ballroom Free Communication 3 Copaxone TIW GLACIER: open-label, randomized



daily in RRMS




FC3.2

15:30 - 17:00

Fri - 9/12

Grand Ballroom Free Communication 3 Copaxone + Estriol A combination trial of estriol plus glatiramer

acetate in relapsing-remitting multiple sclerosis:

effect on disabilities

R Voskuhl, H Wang, G Lee, B Giesser, CH Tse, R

Elashoff, Estriol Relapse Trial Study Group

FC3.3

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 19: Receptos Receptos


●14:45 - 16:15

Sat - 9/13

Auditorium Late Breaking News RPC1063 Phase 2 results of the RADIANCE trial: a





Frohna, K Selmaj

LB1.1

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 20: XenoPort Xenoport


●

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 XP23829 Steady state pharmacokinetics and blood



multiple sclerosis


LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 21: Other Other


10:00 - 11:30

Thu - 9/11

Auditorium Parallel Session 1: Cell-based

Therapies

MSCs Phase I trial of intravenous autologous culture-

expanded mesenchymal stem cell transplantation

in multiple sclerosis

JA Cohen, PB Imrey, SM Planchon, RA Bermel, E

Fisher, RJ Fox, A Bar-Or, SL Sharp, TT

Skaramagas, P Jagodnik, M Karafa, S Morrison, J

Reese Koc, SL Gerson, HM Lazarus

PS1.5

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 2B3-201 Double-blind, placebo- and active comparator-

controlled study in healthy males to assess the

safety, pharmacokinetics and -dynamics of 2B3-

201

W Gladdines, K Kanhai, I Stavrakaki, RGJA

Zuiker, PJ Gaillard, GJ Groeneveld, F Lönnqvist

P076

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Alpha B-Crystallin A randomized, double-blind, placebo-controlled

phase IIa study of alpha B-crystallin in multiple

sclerosis

JM van Noort, M Bsibsi, PJ Nacken, R Verbeek,

EH Venneker

P082

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 GNbAC1 GNbAC1, a monoclonal antibody against the

MSRV envelope protein, pharmacodynamic

responses in patients with multiple sclerosis

F Curtin P092

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 NKT Cell Ligand

OCH

First-in-human phase 1 study of invariant NKT cell

ligand OCH

D Noto, M Araki, W Sato, T Okamoto, M Murata,

S Miyake, T Yamamura,

P093

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 Copaxone +

Interferon Beta-1a

Physician and participant treatment guesses in

the double-blind CombiRx study

SS Cofield, T Gustafson, GR Cutter, JS Wolinsky,

FD Lublin, The CombiRx Investigators

P099

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 MIS416 Innate immune modulator MIS416 enhances

systemic levels of negative regulators of

inflammation in phase 2a clinical trial plasma

samples

G Webster, V Pearson, R Girvan P111

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 MIF Inhibitor A novel MIF inhibitor as therapy for multiple

sclerosis and stroke

AA Vandenbark, R Meza-Romero, G Benedek, H

Offner,

P310

15:30 - 17:00

Thu - 9/11

Hall C Poster Session 1 HPP971 The novel Bach1 inhibitor HPP971 uniquely

activates Nrf2 and reduces disease severity in a

mouse model of experimental autoimmune

encephalomyelitis

S-K Kim, J Kassis, O Attucks, J Freeman, Z

Zhong, S Gupta, S Victory, D Polisetti, A Mjalli, R

Andrews, M Kostura, M Guzel, B Gaddam, S

Weaver, K Sakmann, ST Davis

P396

08:15 - 09:15

Fri - 9/12

Small Ballroom

(302-304-306)

Parallel Session 10: Immune

mechanisms

Copaxone +

Interferon Beta-1a

Early on-treatment T2 and T1 subtraction MRI

predicts imaging and clinical outcomes in the

CombiRx cohort

F Lalys, L Freeman, TD Staewen, JA Lincoln, F

Nelson, S Datta, PA Narayana, SS Cofield, T

Gustafson, GR Cutter, FD Lublin, JS Wolinsky,

CombiRx Investigators

PS9.6

09:45 - 11:15

Fri - 9/12

Hall C Poster Session 2 NDC-1308 NDC-1308, a gain of function estradiol analog for

inducing remyelination in multiple sclerosis

patients

SH Nye, S Medicetty, BD Trapp, JG Yarger P710

09:45 - 11:15

Fri - 9/12

Hall C Poster Session 2 Anti-SEMA4D mAb Anti- SEMA4D antibody ameliorates pathogenic

processes related to multiple sclerosis

AS Jonason, E Klimatcheva, T Fisher, C Reilly, L

Winter, J Veeraraghavan, M Doherty, C Mallow, J

Seils, H Bussler, S Torno, R Kirk, A Howell, M

Scrivens, L Balch, T Pandina, W Wang, E Evans,

WJ Bowers, M Paris, J Leonard, V Iddison, E

Smith, M Zauderer

P712

09:45 - 11:15

Fri - 9/12

Hall C Poster Session 2 KB3944 KB3944, a selective estrogen receptor beta

agonist, in preclinical development for

neuroprotective and regenerative therapy of

multiple sclerosis

P Fagergren, S Tiwari-Woodruff, M Osterlund P715

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 MSCs Cytogenetic analysis of culture-expanded human

mesenchymal stem cells used in a phase I clinical

trial in multiple sclerosis

SM Planchon, I Warshawsky, JS Reese, KM

Drake, JA Cohen

P890

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 MSCs Immune function monitoring in a phase I trial of

autologous culture-expanded mesenchymal stem

cell transplantation for relapsing multiple sclerosis

A Bar-Or, M-N Boivin, A Rozenberg, T Johnson, C

Belabani, G Morisse, J Sirois, S Lai Wing Sun, S

Vanamala, A Del Rosario Villalobos, J Reese Koc,

S Morrison, RA Bermel, PB Imrey, SM Planchon,

JA Cohen

P892

14:45 - 16:15

Fri - 9/12

Hall C Poster Session 2 ACTiMuS Assessment of bone marrow-derived cell therapy

in progressive multiple sclerosis (ACTiMuS)

CM Rice, DI Marks, Y Ben-Shlomo, N Evangelou,

C Metcalfe, P Walsh, DA Cottrell, NM Kane, A

Wilkins, NJ Scolding

P902

14:45 - 16:15

Sat - 9/13

Outside Hall C Late Breaking News Posters GNbAC1 HERV-W envelope protein inhibits

oligodendroglial cell differentiation which can be

abrogated by the neutralizing antibody GNbAC1

D Kremer, M Foerster, T Schichel, P Goettle, H-P

Hartung, H Perron, P Kuery

LBP15

14:45 - 16:15

Sat - 9/13

Outside Hall C Late Breaking News Posters GNbAC1 Follow-up of MS patients from phase IIa clinical

study of GNbAC1 reveals unexpected decrease of

HERV-W endogenous retrovirus genes

expression

R Faucard, A Madeira, N Gehin, T Derfuss, H-P

Hartung, R Du Pasquier, L Kappos, P Lalive, H

Porchet, AB Lang, F Curtin, HJF Perron

LBP16

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


All Sessions

Exhibit 22: Wednesday – September 10, 2014 Wednesday - September 10, 2014


08:00 - 09:30 304 Teaching Course 1: Current

controversy in management:

Interactive case discussion

General Current controversy in management: interactive

case discussion

AE Miller TC1.1




General Treating CIS and early RRMS: pros and cons A Goodyear TC2.1

●08:00 - 09:30 312 Teaching Course 2: How do I




●08:00 - 09:30 312 Teaching Course 2: How do I




or escalated

BC Kieseier TC2.3

08:00 - 09:30 310 Teaching Course 3: Symptom

management

General Symptom management - focus on gait impairment A Goodman TC3.1


management

General Effective management of spasticity AJ Thompson TC3.2


management

General Exercise therapy as symptomatic treatment U Dalgas TC3.3

08:00 - 09:30 313 Teaching Course 5: Clinically


General Radiologically isolated syndrome: pre-

symptomatic MS?

DT Okuda TC5.1

08:00 - 09:30 313 Teaching Course 5: Clinically


General How can we treat and manage CIS patients? M Tintore TC5.3

●08:00 - 09:30 306 Teaching Course 7: Imaging small


(MAGNIMS)


●08:00 - 09:30 306 Teaching Course 7: Imaging small


(MAGNIMS)


10:00 - 11:30 310 Teaching Course 8: Update in

pediatric MS

General Diagnosis of MS and acute demyelinating

disorders in children

C Hemingway TC8.1


pediatric MS

General Emerging therapies and clinical trials in pediatric

MS

T Chitnis TC8.2


pediatric MS

General MRI: role in assessment of MS disease activity

and disease impact in patients with MS onset

during childhood

BL Banwell TC8.3

●10:00 - 11:30 312 Teaching Course 9: Differential



●10:00 - 11:30 312 Teaching Course 9: Differential



LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 23: Wednesday – September 10, 2014 Wednesday - September 10, 2014




General MS differential diagnoses E Waubant TC9.3

10:00 - 11:30 302 Teaching Course 10:


pathophysiology and

immunotherapy

General Inadequate activation of T cells in MS: possible

mechanisms involved

RS LIBLAU TC10.1

10:00 - 11:30 302 Teaching Course 10:


pathophysiology and

immunotherapy

General Contribution of B cell: T cell interactions to CNS

inflammation in MS

A Bar-Or TC10.2

10:00 - 11:30 302 Teaching Course 10:


pathophysiology and

immunotherapy

General Immune cell trafficking to the CNS, mechanisms

and therapeutic implications

MH Han TC10.3

●10:00 - 11:30 311 Teaching Course 11: MRI issues in






studies

E Fisher TC11.2




10:00 - 11:30 313 Teaching Course 12: Neuro-

opthalmology update

General Visual manifestations of CNS demyelinating

disorders

FE Costello TC12.1

10:00 - 11:30 313 Teaching Course 12: Neuro-

opthalmology update

General The role of visual outcomes in MS clinical trials LJ Balcer TC12.3

●10:00 - 11:30 304 Teaching Course 13: Assessing the


design


design

F Lublin TC13.1



design

General Assessing treatment efficacy in MS: observational

studies vs clinical trials

MP Sormani TC13.2

●10:00 - 11:30 304 Teaching Course 13: Assessing the


design




GR Cutter TC13.3

10:00 - 11:30 306 Teaching Course 14:



General The manifestations of cognitive and psychiatric

disorders in MS and assessment strategies

R Benedict TC14.1

10:00 - 11:30 306 Teaching Course 14:



General Treatment of disorders of mood and affect in MS

patients

A Feinstein TC14.2

10:00 - 11:30 306 Teaching Course 14:



General Treatment of cognitive dysfunction in MS patients MP Amato TC14.3


Symposium



Sanofi - - - - -


Symposium




LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 24: Thursday – September 11, 2014 Thursday - September 11, 2014


●


Symposium




Practice

Sanofi - - - - -

●09:00 - 10:00 Auditorium Plenary Session 1 General Approaching the cause of multiple sclerosis DA Hafler PL1.1

●10:30 - 12:00 Auditorium Parallel Session 1: Cell-based

Therapies



C Laule PS1.2

10:30 - 12:00 Auditorium Parallel Session 1: Cell-based

Therapies

MSCs Phase I trial of intravenous autologous culture-

expanded mesenchymal stem cell transplantation

in multiple sclerosis

JA Cohen, PB Imrey, SM Planchon, RA Bermel, E

Fisher, RJ Fox, A Bar-Or, SL Sharp, TT

Skaramagas, P Jagodnik, M Karafa, S Morrison, J

Reese Koc, SL Gerson, HM Lazarus

PS1.5


Symposium


MS

Novartis - - - - -


(302-304-306)

Parallel Session 4: EAE and other

animal models

General What can EAE teach us about MS? JM Goverman, MC Johnson, ER Pierson, SB

Simmons

PS4.1

14:00 - 15:30 Auditorium Parallel Session 6: Risk

management with MS Therapy

General PML with novel immunotherapies: Is there light at

the end of the tunnel?

R Gold PS6.1

15:30 - 17:00 Hall C Poster Session 1 Ampyra Treatment patterns and budget impact of

dalfampridine in multiple sclerosis: a retrospective

claims database analysis

S Palli, M Sidovar, M Grabner, A Guo P010

15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Cost-effectiveness of alemtuzumab vs

subcutaneous interferon beta-1a for treatment of

active relapsing-remitting multiple sclerosis: payer

perspective

C Celestin, GR Cutter, AJ Coles, A Reimers, DH

Margolin, on behalf of the CARE-MS I and II

Investigators

P013

●15:30 - 17:00 Hall C Poster Session 1 Aubagio MRI outcomes in patients with early multiple





AC in Houston, TX

P040

15:30 - 17:00 Hall C Poster Session 1 Laquinimod Effect of laquinimod on gray matter and white

matter atrophy in relapsing-remitting multiple

sclerosis: analysis of the BRAVO phase III trial

K Nakamura, TL Vollmer, T Gorfine, V Knappertz,

DL Arnold

P041

●15:30 - 17:00 Hall C Poster Session 1 Plegridy Peginterferon beta-1a may improve recovery



study



P042

●15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Efficacy and safety of alemtuzumab in patients



study





P043

●15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves quality of life in relapsing-





P044

●15:30 - 17:00 Hall C Poster Session 1 Aubagio Evaluating the effect of teriflunomide in subgroups




Truffinet, L Kappos

P046

15:30 - 17:00 Hall C Poster Session 1 Gilenya The effects of age and gender on brain volume in

FREEDOMS, FREEDOMS II and TRANSFORMS

phase 3 studies

E-W Radue, JS Wolinsky, D Tomic, DA Häring, P

Chin, F Barkhof

P047

15:30 - 17:00 Hall C Poster Session 1 Ofatumumab Follow-up data from the Mirror study: a dose-

ranging study of subcutaneous ofatumumab in

subjects with relapsing-remitting multiple sclerosis

PS Sorenson, ST Kavanagh, DJ Austin, RA

Grove, MC Lopez, JM Tolson, SA Van Meter, A

Bar-Or

P048

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




●15:30 - 17:00 Hall C Poster Session 1 Siponimod Modeling dose-PK-lymphocytes relationship under





P050

●

15:30 - 17:00 Hall C Poster Session 1 Daclizumab Brain MRI results of DECIDE: a randomized,


RRMS patients




J Elkins

P051

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Effect of bismuth subsalicylate on gastrointestinal

events associated with delayed-release dimethyl

fumarate: a double-blind, placebo-controlled study

C Tornatore, J Li, TS Ma, C von Hehn, J Walsh, J

Zambrano

P052

●15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Comparable clinical and MRI efficacy of



analysis



P053

15:30 - 17:00 Hall C Poster Session 1 Laquinimod Switching from interferon β-1a IM to laquinimod:

safety and efficacy results from the BRAVO study

extension

TL Vollmer, N Ashtamker, Y Sidi, D Ladkani, T

Gorfine, PS Sørensen

P054

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Delayed-release dimethyl fumarate and disability

assessed by the multiple sclerosis functional

composite: integrated analysis of DEFINE and

CONFIRM

G Giovannoni, R Gold, L Kappos, DL Arnold, A

Bar-Or, NC Kurukulasuriya, M Yang, SP Sarda

P057

15:30 - 17:00 Hall C Poster Session 1 Aubagio The efficacy of teriflunomide is evident before

steady-state plasma concentrations are reached

JS Wolinsky, D Dukovic, P Truffinet, L Kappos,

for the investigators of the Phase Proof-of-

Concept, TEMSO, TOWER and TOPIC Studies,

and the MRI-AC in Houston, TX

P058

●




ENDORSE




P059

15:30 - 17:00 Hall C Poster Session 1 Aubagio Effect of teriflunomide on lymphocyte and

neutrophil counts: pooled analyses from four

placebo-controlled studies

G Comi, MS Freedman, L Kappos, AE Miller, TP

Olsson, JS Wolinsky, M Benamor, D Dukovic, P

Truffinet, PW O'Connor

P060

15:30 - 17:00 Hall C Poster Session 1 Laquinimod Consistent effect of laquinimod on relapse-related

and disability progression-related endpoints

G Comi, TL Vollmer, L Kappos, X Montalban, T

Gorfine, N Sasson, V Knappertz,

P061

●15:30 - 17:00 Hall C Poster Session 1 Laquinimod Clinical efficacy of laquinimod 0.6mg once-daily in





Knappertz,

P062

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Long-term efficacy of delayed-release dimethyl

fumarate in newly diagnosed patients with RRMS:

an integrated analysis of DEFINE, CONFIRM, and

ENDORSE

R Gold, G Giovannoni, JT Phillips, RJ Fox, A

Zhang, NC Kurukulasuriya

P064

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Efficacy of delayed-release dimethyl fumarate for

RRMS in prior interferon users in the DEFINE and

CONFIRM studies

Ó Fernández, G Giovannoni, RJ Fox, R Gold, JT

Phillips, M Okwuokenye, A Zhang, NC

Kurukulasuriya

P065

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Long-term follow-up of the safety of delayed-

release dimethyl fumarate in RRMS: interim

results from the ENDORSE extension study

C Pozzilli, JT Phillips, RJ Fox, K Selmaj, R Zhang,

M Novas, MT Sweetser, R Gold

P066

●15:30 - 17:00 Hall C Poster Session 1 Plegridy Effect of peginterferon beta-1a on MRI measures





P067

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




15:30 - 17:00 Hall C Poster Session 1 Laquinimod Laquinimod effect on confirmed disability

progression: minimal mediation by relapse or T2

lesions reduction

MP Sormani, TL Vollmer, G Comi, Y Sidi, JR

Steinerman, T Gorfine, V Knappertz,

P069

15:30 - 17:00 Hall C Poster Session 1 Laquinimod Laquinimod disability progression effects are

maintained with increasingly rigorous confirmation

time intervals

G Comi, TL Vollmer, L Kappos, X Montalban, N

Sasson, T Gorfine, V Knappertz,

P070

15:30 - 17:00 Hall C Poster Session 1 Laquinimod Temporal pattern of laboratory changes with

laquinimod treatment

TL Vollmer, G Comi, PS Sørensen, N Sasson, T

Gorfine, V Knappertz,

P071

15:30 - 17:00 Hall C Poster Session 1 Tysabri Quantifying the effect of natalizumab on the total

disability burden of MS patients in AFFIRM using

an exploratory area under the curve analysis

RA Rudick, S Shang, Q Dong, D Paes, D Mikol, S

Belachew

P073

●15:30 - 17:00 Hall C Poster Session 1 Plegridy Impact of peginterferon beta-1a treatment and





P074

15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves MRI outcomes regardless

of subgroup versus interferon beta-1a in relapsing-

remitting MS patients who relapsed on prior

therapy

F Barkhof, E Fisher, J Palmer, DH Margolin, DL

Arnold, on behalf of the CARE-MS II Investigators

P075

15:30 - 17:00 Hall C Poster Session 1 2B3-201 Double-blind, placebo- and active comparator-

controlled study in healthy males to assess the

safety, pharmacokinetics and -dynamics of 2B3-

201

W Gladdines, K Kanhai, I Stavrakaki, RGJA

Zuiker, PJ Gaillard, GJ Groeneveld, F Lönnqvist

P076

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Lymphocyte count reductions with delayed-

release dimethyl fumarate: integrated analysis of

the phase 2, phase 3, and extension studies

RJ Fox, A Chan, R Gold, JT Phillips, K Selmaj, R

Zhang, H Yuan, M Novas, V Viglietta, NC

Kurukulasuriya

P077

15:30 - 17:00 Hall C Poster Session 1 Aubagio Long-term MRI outcomes from patients treated

with teriflunomide: results from a phase 2

extension study

DBK Li, AL Traboulsee, P Truffinet, D Dukovic,

PW O’Connor

P079

15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Convenience of glatiramer acetate 40mg/mL three

times weekly: evidence from the GLACIER study

JS Wolinsky, TE Borresen, DW Dietrich, BF

Gilder, Y Sidi, JR Steinerman, V Knappertz, S

Kolodny, GLACIER Study Group

P080

15:30 - 17:00 Hall C Poster Session 1 Gilenya Time to brain atrophy is prolonged in continuously

fingolimod-treated MS patients vs placebo or

interferon beta 1-a in phase 3 studies of

fingolimod

D Häring, D Tomic, D Piani Meier, N Sfikas, P

Chin, G Francis

P081

15:30 - 17:00 Hall C Poster Session 1 Alpha B-Crystallin A randomized, double-blind, placebo-controlled

phase IIa study of alpha B-crystallin in multiple

sclerosis

JM van Noort, M Bsibsi, PJ Nacken, R Verbeek,

EH Venneker

P082

15:30 - 17:00 Hall C Poster Session 1 Gilenya Safety and tolerability of fingolimod in relapsing-

remitting multiple sclerosis: results from a large

open-label clinical trial

A Laroni, D Brogi, V Brescia Morra, L Guidi, C

Pozzilli, G Comi, A Lugaresi, R Turrini, D

Raimondi, A Uccelli, GL Mancardi, EAP

Investigators

P083

●15:30 - 17:00 Hall C Poster Session 1 Plegridy Safety and tolerability of peginterferon beta-1a in





P085

15:30 - 17:00 Hall C Poster Session 1 Gilenya An interim analysis of the German START-study

confirms the good cardiac safety profile of

fingolimod

V Limmroth, S Hoyer, M Lang, S Schmidt, T

Ziemssen

P086

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab reduces disease activity in

treatment-naive patients with highly active


S Krieger, C Lubetzki, J Palmer, DH Margolin, on

behalf of CARE-MS I Study Investigators

P088

15:30 - 17:00 Hall C Poster Session 1 Betaseron Interferon beta-1b in treatment-naïve paediatric

patients with relapsing-remitting MS: baseline

data from the BETAPAEDIC study

J Gärtner, W Brück, A Weddige, K Reinhardt, JP

Bugge, The BETAPAEDIC Study Group

P089

●

15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Efficacy and safety of alemtuzumab in treatment-







P090

15:30 - 17:00 Hall C Poster Session 1 GNbAC1 GNbAC1, a monoclonal antibody against the

MSRV envelope protein, pharmacodynamic

responses in patients with multiple sclerosis

F Curtin P092

15:30 - 17:00 Hall C Poster Session 1 NKT Cell Ligand

OCH

First-in-human phase 1 study of invariant NKT cell

ligand OCH

D Noto, M Araki, W Sato, T Okamoto, M Murata,

S Miyake, T Yamamura,

P093

●

15:30 - 17:00 Hall C Poster Session 1 Daclizumab Safety and tolerability of daclizumab HYP






J Elkins

P094

15:30 - 17:00 Hall C Poster Session 1 Aubagio Efficacy of teriflunomide in patients with early

stage MS: analysis of the TOPIC study using

2010 McDonald diagnostic criteria



AC in Houston, TX

P095

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Differential recovery from relapse between

treatment groups in the CONFIRM study of


A Chan, JT Phillips, RJ Fox, A Zhang, M

Okwuokenye, NC Kurukulasuriya

P096

●15:30 - 17:00 Hall C Poster Session 1 Aubagio Pooled safety analyses from the teriflunomide





P097

15:30 - 17:00 Hall C Poster Session 1 Copaxone +

Interferon Beta-1a

Physician and participant treatment guesses in

the double-blind CombiRx study

SS Cofield, T Gustafson, GR Cutter, JS Wolinsky,

FD Lublin, The CombiRx Investigators

P099

●

15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Indirect comparison of glatiramer acetate



statistical model



P100

15:30 - 17:00 Hall C Poster Session 1 Gilenya Effect of fingolimod on evolution of baseline

enhancing MRI lesions into persistent T1

hypointense lesions: post hoc analysis of the

FREEDOMS study

EW Radue, T Sprenger, A de Vera, G Francis, E

Rochotte, D Tomic, L Kappos

P101

15:30 - 17:00 Hall C Poster Session 1 Rebif No evident disease activity at 24 weeks in patients

with relapsing MS treated with interferon β-1a SC

vs. interferon β-1a IM in the EVIDENCE study

PK Coyle, J Fang, A Hassan, C Cha, F Dangond,

AT Reder

P102

●15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves MRI outcomes in






P103

15:30 - 17:00 Hall C Poster Session 1 Rebif No evident disease activity in relapsing MS

patients treated with interferon β-1a SC vs.

interferon β-1a IM: subgroup analyses of the

EVIDENCE study

PK Coyle, J Fang, A Hassan, C Cha, F Dangond,

AT Reder

P104

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




●15:30 - 17:00 Hall C Poster Session 1 Daclizumab Integrated analysis of daclizumab HYP



15:30 - 17:00 Hall C Poster Session 1 Gilenya 24 month PANGAEA: a 5-year non-interventional

study of safety, efficacy and pharmacoeconomic

data for fingolimod patients in daily clinical

T Ziemssen, A Fuchs, H-J Schwarz, T van

Lokven, C Cornelissen

P107

15:30 - 17:00 Hall C Poster Session 1 Tecfidera Efficacy of delayed-release dimethyl fumarate in

multiple sclerosis patients with moderate

disability: an integrated analysis of the phase 3

studies

M Hutchinson, A Zhang, M Yang, M Okwuokenye,

NC Kurukulasuriya, RJ Fox, R Gold

P108

●

15:30 - 17:00 Hall C Poster Session 1 Siponimod Modeling concentration-efficacy relationship for



reduction


●




ENDORSE studies



Viglietta, RJ Fox

P110

15:30 - 17:00 Hall C Poster Session 1 MIS416 Innate immune modulator MIS416 enhances

systemic levels of negative regulators of

inflammation in phase 2a clinical trial plasma

samples

G Webster, V Pearson, R Girvan P111

15:30 - 17:00 Hall C Poster Session 1 Gilenya Impact of fingolimod on achieving no evidence of

disease activity in pre-treated patients with high

disease activity in FREEDOMS and FREEDOMS

II

N Bergvall, D Tomic, N Sfikas, L Kappos P112

15:30 - 17:00 Hall C Poster Session 1 Tysabri Natalizumab decreases progression of disability in

RRMS patients as measured by the composite

EDSS-Plus in AFFIRM

Q Dong, RA Rudick, D Paes, D Mikol, S Belachew P113

●15:30 - 17:00 Hall C Poster Session 1 BIIB033 Potential biomarkers of BIIB033 activity in phase 1

clinical studies


Yang, D Cadavid

P262

●

15:30 - 17:00 Hall C Poster Session 1 Gilenya vs.

Tecfidera




pharmacy data


15:30 - 17:00 Hall C Poster Session 1 Gilenya Including threshold rates of brain volume loss in

the definition of disease-activity-free in multiple

sclerosis using fingolimod phase 3 data

N De Stefano, T Sprenger, MS Freedman, B

Cree, MP Sormani, DA Häring, G Francis, D Piani

Meier, D Tomic, L Kappos

P290

15:30 - 17:00 Hall C Poster Session 1 Tecfidera vs.

Gilenya

Comparative tolerability and efficacy of dimethyl

fumarate and fingolimod in multiple sclerosis

S Cohn, R Bermel, C Hara, C Hersh, RJ Fox, J

Cohen, D Ontaneda

P300

15:30 - 17:00 Hall C Poster Session 1 General Time to relapse among propensity score matched

patients receiving disease modifying therapy for

multiple sclerosis

BH Johnson, MM Bonafede, C Watson P304

●15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Reduced frequency and severity of injection site


times weekly dosing



P306

15:30 - 17:00 Hall C Poster Session 1 General Real-world titration of disease modifying therapies

in the treatment of multiple sclerosis: findings

from a survey of neurologists

T Nazareth, J Marvel, S Sikirica, J Xie, W

Reichmann, C Zhao, R Sasane

P307

●15:30 - 17:00 Hall C Poster Session 1 Tecfidera Gastrointestinal tolerability of delayed-release





P309

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




15:30 - 17:00 Hall C Poster Session 1 MIF Inhibitor A novel MIF inhibitor as therapy for multiple

sclerosis and stroke

AA Vandenbark, R Meza-Romero, G Benedek, H

Offner,

P310

●15:30 - 17:00 Hall C Poster Session 1 General The changing face of MS: does ARR vary by

epoch?


15:30 - 17:00 Hall C Poster Session 1 HPP971 The novel Bach1 inhibitor HPP971 uniquely

activates Nrf2 and reduces disease severity in a

mouse model of experimental autoimmune

encephalomyelitis

S-K Kim, J Kassis, O Attucks, J Freeman, Z

Zhong, S Gupta, S Victory, D Polisetti, A Mjalli, R

Andrews, M Kostura, M Guzel, B Gaddam, S

Weaver, K Sakmann, ST Davis

P396

15:30 - 17:00 Hall C Poster Session 1 Gilenya Sustained low rate of brain volume loss under

long-term fingolimod treatment in relapsing

multiple sclerosis: results from the LONGTERMS

study

EW Radue, F Barkhof, J Cohen, R Gottschalk, Y

Zhang, L Cappiello, P von Rosenstiel, L Kappos

P439

15:30 - 17:00 Hall C Poster Session 1 Rebif Evolution of gadolinium-enhancing lesions into

chronic black holes in patients treated with

subcutaneous interferon β-1a in PRISMS and

SPECTRIMS

A Traboulsee, D Li, Y Zhao, R Tam, G Zhao, Y

Cheng, A Riddehough, F Dangond, J Fang, L

Kappos, on behalf of the PRISMS and

SPECTRIMS Working Groups

P470

15:30 - 17:00 Hall C Poster Session 1 Rebif Natural evolution of gadolinium-enhancing lesions

into chronic black holes in multiple sclerosis:

analysis of PRISMS and SPECTRIMS placebo

arms

A Traboulsee, D Li, Y Zhao, R Tam, G Zhao, Y

Cheng, A Riddehough, F Dangond, J Fang, L

Kappos, on behalf of the PRISMS and

SPECTRIMS Working Groups

P473

17:00 - 17:45 Auditorium Hot Topic 2: New routes of drug

development

General Repurposing drugs for disease modification in

multiple sclerosis

K Schmierer HT2.1


development

General A perspective on generic medications to treat MS JA Cohen HT2.2


development

General From genetic findings to drug discovery: taking

the first step

NA Patsopoulos, JM Replogle, HT2.3


(302-304-306)

Hot Topic 3: Symptomatic and

rehabilitation strategies

General Cognitive impairment MP Amato HT3.1


Symposium



Teva - - - - -

●19:15 - 20:15 Small Ballroom Satellite Symposium Satellite

Symposium


Patients


LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 30: Friday – September 12, 2014 Friday - September 12, 2014


●

08:15 - 09:15 Auditorium Free Communication 1 Daclizumab Primary results of DECIDE: a randomized, double-



patients




J Elkins

FC1.1

●

08:15 - 09:15 Auditorium Free Communication 1 Generic Copaxone Generic glatiramer acetate is equivalent to



sclerosis




Study Group

FC1.2

08:15 - 09:15 Auditorium Free Communication 1 Laquinimod Long-term follow-up of laquinimod in patients with


G Comi, TL Vollmer, N Ashtamker, Y Sidi, D

Ladkani, T Gorfine, PS Sørensen

FC1.3

●08:15 - 09:15 Auditorium Free Communication 1 Alemtuzumab Disease-free outcomes with alemtuzumab: 3-year




Investigators

FC1.4


(302-304-306)

Free Communication 2 Gilenya Inclusion of brain volume loss in a revised

measure of multiple sclerosis disease-activity

freedom: the effect of fingolimod

L Kappos, E-W Radue, MS Freedman, B Cree,

MP Sormani, N Sfikas, G Francis, D Tomic, D

Piani Meier, N De Stefano

FC1.5

●08:15 - 09:15 Small Ballroom

(302-304-306)

Free Communication 2 Alemtuzumab Alemtuzumab improves MRI outcomes in



CARE-MS I




FC2.2


(302-304-306)






FC2.3


(302-304-306)




sclerosis




FC2.4

●08:15 - 09:15 Grand Ballroom Free Communication 3 Plegridy Clinical efficacy of peginterferon beta-1a in






FC2.5

●08:15 - 09:15 Grand Ballroom Free Communication 3 Copaxone TIW GLACIER: open-label, randomized



daily in RRMS




FC3.2

08:15 - 09:15 Grand Ballroom Free Communication 3 Copaxone + Estriol A combination trial of estriol plus glatiramer

acetate in relapsing-remitting multiple sclerosis:

effect on disabilities

R Voskuhl, H Wang, G Lee, B Giesser, CH Tse, R

Elashoff, Estriol Relapse Trial Study Group

FC3.3


(302-304-306)

Parallel Session 7: Biomarkers Tecfidera Long-term follow-up of the effect of delayed-

release dimethyl fumarate on no evident disease

activity in patients with multiple sclerosis

G Giovannoni, R Gold, RJ Fox, L Kappos, T

Phillips, A Zhang, NC Kurukulasuriya, E Havrdova

FC3.5


(302-304-306)


therapies

S Dhib-Jalbut PS7.2


(302-304-306)

Parallel Session 7: Biomarkers General Immunological biomarkers that identify MS

patients with high probability of being free of

disease activity if treated with IFN-beta

JC Alvarez-Cermeño, R Alenda, L Costa-

Frossard, R Alvarez-Lafuente, C Picon, M Espiño,

E Roldan, R Arroyo, E Rodriguez-Martin, LM Villar

PS7.3

09:45 - 11:15 Grand Ballroom Parallel Session 8: Assessing

neuroprotection

General Pathways to neurodegeneration: insights from

imaging in MS and other neurodegenerative

disorders

M Inglese PS8.1

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




●09:45 - 11:15 Grand Ballroom Parallel Session 8: Assessing

neuroprotection



J Chataway PS8.2

09:45 - 11:15 Auditorium Parallel Session 9: Treatment


General Differentiation and quantification of inflammation,

demyelination, and axon injury in human multiple

sclerosis using diffusion basis spectrum imaging

Y Wang, P Sun, Q Wang, C-W Chiang, RE

Schmidt, RT Naismith, AH Cross, S-K Song

PS8.6



General Is no evidence of disease activity a realistic

treatment target?

H-P Hartung PS9.1



General Treatment algorithms in patients with ongoing

disease activity

X Montalban PS9.2


(302-304-306)

Parallel Session 10: Immune

mechanisms

Copaxone +

Interferon Beta-1a

Early on-treatment T2 and T1 subtraction MRI

predicts imaging and clinical outcomes in the

CombiRx cohort

F Lalys, L Freeman, TD Staewen, JA Lincoln, F

Nelson, S Datta, PA Narayana, SS Cofield, T

Gustafson, GR Cutter, FD Lublin, JS Wolinsky,

CombiRx Investigators

PS9.6


Symposium



Multiple Sclerosis

Teva - - - - -

13:15 - 14:45 Grand Ballroom Parallel Session 11: Gray matter

pathology and mechanisms of

progression

General Demyelinating lesions in multiple sclerosis:

experimental evidence indicating why, how and

where they may form

RA Desai, AL Davies, M Kasti, F Laulund, KJ

Smith

PS10.3

13:15 - 14:45 Auditorium Parallel Session 12: Study design

and endpoints

General Is primary progressive MS a distinct disease? S Vukusic PS11.2

13:15 - 14:45 Auditorium Parallel Session 12: Study design

and endpoints

General Pragmatic clinical trials and observational studies M Trojano PS12.2


(302-304-306)

Hot Topic 4: Remyelination General Defining brain volume cut-offs to predict disability

progression in MS: an analysis of a large cohort of

relapsing-remitting MS patients

MP Sormani, L Kappos, EW Radue, J Cohen, F

Barkhof, T Sprenger, D Piani Meier, D Häring, D

Tomic, N De Stefano

PS12.3

14:45 - 16:15 Hall C Poster Session 2 Gilenya Identification of tissue-specific MRI markers to

assess protection and repair in response to

fingolimod

C Berrios-Otero, L Fleysher, J Zhang, E

Fieremans, G John, M Inglese

P497

14:45 - 16:15 Hall C Poster Session 2 M356 Comparative efficacy between a generic (M356)

and brand Copaxone® (glatiramer acetate

injection) in an animal model of multiple sclerosis

C Honan, TC Ganguly, I Fier, GV Kaundinya P600

14:45 - 16:15 Hall C Poster Session 2 General Histamine H3 receptor negatively regulates

oligodendrocyte differentiation and myelination

RR Wang, Y Chen, T Guo, W Zhen, TB Guo, RY

Zhao, AA Liu, JP Rubio, D Krull, J Lu, M Song, P

Thompson, S Wang, JC Richardson

P621

14:45 - 16:15 Hall C Poster Session 2 General Optic neuritis associated with multiple sclerosis:

VEPs sensitive in acute phase, OCT useful in

chronic phase

G Di Maggio, RI Santangelo, S Guerrieri, L

Ferrari, S Medaglini, M Rodegher, B Colombo, L

Moiola, U Del Carro, V Martinelli, G Comi, L

Leocani

P676

14:45 - 16:15 Hall C Poster Session 2 General Visual evoked potentials and optic coherence

tomography in monitoring involvement of visual

pathways in multiple sclerosis

L Leocani, S Guerrieri, G Di Maggio, R

Santangelo, L Ferrari, S Medaglini, M Rodegher,

B Colombo, L Moiola, U Del Carro, V Martinelli, G

Comi

P704

14:45 - 16:15 Hall C Poster Session 2 NDC-1308 NDC-1308, a gain of function estradiol analog for

inducing remyelination in multiple sclerosis

patients

SH Nye, S Medicetty, BD Trapp, JG Yarger P710

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014




14:45 - 16:15 Hall C Poster Session 2 Anti-SEMA4D mAb Anti- SEMA4D antibody ameliorates pathogenic

processes related to multiple sclerosis

AS Jonason, E Klimatcheva, T Fisher, C Reilly, L

Winter, J Veeraraghavan, M Doherty, C Mallow, J

Seils, H Bussler, S Torno, R Kirk, A Howell, M

Scrivens, L Balch, T Pandina, W Wang, E Evans,

WJ Bowers, M Paris, J Leonard, V Iddison, E

Smith, M Zauderer

P712

14:45 - 16:15 Hall C Poster Session 2 KB3944 KB3944, a selective estrogen receptor beta

agonist, in preclinical development for

neuroprotective and regenerative therapy of

multiple sclerosis

P Fagergren, S Tiwari-Woodruff, M Osterlund P715

14:45 - 16:15 Hall C Poster Session 2 General Small molecule inducers of oligodendrocyte

differentiation

B Bai, R Avila, M Torres-Castillo, S Lunn, S

Medicetty, B Trapp

P721

●14:45 - 16:15 Hall C Poster Session 2 GSK239512 The effects of GSK239512 on lesion





Arnold

P726

14:45 - 16:15 Hall C Poster Session 2 General A high throughput flow cytometry based approach

to assess the differentiation of oligodendrocyte

precursor cells into mature oligodendrocytes

C Hollins, H Sandig, C Glover, C Jones, M

Sleeman

P728

●14:45 - 16:15 Hall C Poster Session 2 BIIB033 A phase II study of the anti-LINGO-1 monoclonal






P731

14:45 - 16:15 Hall C Poster Session 2 General Clinical and molecular markers that predict

severity of relapsing-remitting MS (RRMS)

disease outcomes

J Goyal, J Bienkowska, R Hosur, M Yang, S

Feng, V Viglietta, D Mikol

P761

14:45 - 16:15 Hall C Poster Session 2 Rebif Assessing a predictive score for long-term

disability progression in relapsing-remitting

multiple sclerosis: 7/8-year follow-up in the

PRISMS study

M Freedman, A-F Ben-Amor, E Aycardi, D Issard,

F Casset-Semanaz, M-P Sormani

P765

14:45 - 16:15 Hall C Poster Session 2 Rebif Assessing a predictive score for disease activity in

secondary progressive multiple sclerosis: post-

hoc analysis of data from the SPECTRIMS study

M Freedman, A-F Ben-Amor, E Aycardi, D Issard,

F Casset-Semanaz, M-P Sormani

P766

●14:45 - 16:15 Hall C Poster Session 2 Tysabri Correlations between patient-reported ambulatory



baseline data




P777

14:45 - 16:15 Hall C Poster Session 2 General Identifying an important change threshold for the

Multiple Sclerosis Walking Scale-12 (MSWS-12)

L Mehta, M McNeill, J Hobart, K Wyrwich, JL

Poon, P Auguste, ZJ Zhong, J Elkins

P783

14:45 - 16:15 Hall C Poster Session 2 General Psychometric testing of the early mobility

impairment questionnaire for multiple sclerosis

T Ziemssen, A Mathias, C Coon, S Agarwal, R

Shah, G Phillips

P784

14:45 - 16:15 Hall C Poster Session 2 Ampyra Evaluation of patient health status in the PR-

fampridine ENABLE study using SF-36-derived

utility scores

A Lee, P Wang, M Yeh P785

14:45 - 16:15 Hall C Poster Session 2 Tecfidera An interim analysis of quality of life in patients with

relapsing-remitting multiple sclerosis treated with


M Kita, RJ Fox, R Gold, G Giovannoni, T Phillips,

SP Sarda, M Okwuokenye, J Kong, R Zhang, NC

Kurukulasuriya, L Kappos

P790

●14:45 - 16:15 Hall C Poster Session 2 Plegridy Impact of treatment-related flu-like symptoms and





P799

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014



Key? Time Room Type Title Authors ID

14:45 - 16:15 Hall C Poster Session 2 Alemtuzumab Defining clinical meaning of patient-reported

outcomes with disability assessment in multiple

sclerosis: an analysis of the CARE-MS II study

L Steinman, H Wang, Y Liu, J Palmer, Q Zhang,


P802

14:45 - 16:15 Hall C Poster Session 2 Tecfidera Delayed-release dimethyl fumarate and

pregnancy: preclinical studies and pregnancy

outcomes from clinical trials and postmarketing

experience

R Gold, JT Phillips, E Havrdova, A Bar-Or, L

Kappos, H Yuan, P Valencia, L Oliva, M Novas, J

Li, MT Sweetser, NC Kurukulasuriya, V Viglietta,

RJ Fox

P839

14:45 - 16:15 Hall C Poster Session 2 Alemtuzumab Pregnancy outcomes in the alemtuzumab MS


P McCombe, A Achiron, DH Margolin, J Palmer, P

Oyuela, on behalf of the CAMMS, CARE-MS I,

and CARE-MS II Investigators

P842

14:45 - 16:15 Hall C Poster Session 2 MSCs Cytogenetic analysis of culture-expanded human

mesenchymal stem cells used in a phase I clinical

trial in multiple sclerosis

SM Planchon, I Warshawsky, JS Reese, KM

Drake, JA Cohen

P890

14:45 - 16:15 Hall C Poster Session 2 MSCs Immune function monitoring in a phase I trial of

autologous culture-expanded mesenchymal stem

cell transplantation for relapsing multiple sclerosis

A Bar-Or, M-N Boivin, A Rozenberg, T Johnson, C

Belabani, G Morisse, J Sirois, S Lai Wing Sun, S

Vanamala, A Del Rosario Villalobos, J Reese Koc,

S Morrison, RA Bermel, PB Imrey, SM Planchon,

JA Cohen

P892

14:45 - 16:15 Hall C Poster Session 2 ACTiMuS Assessment of bone marrow-derived cell therapy

in progressive multiple sclerosis (ACTiMuS)

CM Rice, DI Marks, Y Ben-Shlomo, N Evangelou,

C Metcalfe, P Walsh, DA Cottrell, NM Kane, A

Wilkins, NJ Scolding

P902

14:45 - 16:15 Hall C Poster Session 2 Ampyra Walking ability and balance in patients with

multiple sclerosis treated with prolonged-release

fampridine: randomized, double-blind MOBILE

study

R Hupperts, J Lycke, C Short, C Gasperini, M

McNeill, R Medori, L Mehta, J Elkins

P922

14:45 - 16:15 Hall C Poster Session 2 Ampyra Safety, quality of life, and walking ability with PR-

fampridine treatment in clinical practice in France:

interim results of the LIBERATE study

J-P Neau, G Castelnovo, T Soisson, A

Kwiatkowski, M McNeill, M Yeh

P924

●

14:45 - 16:15 Hall C Poster Session 2 XP23829 Steady state pharmacokinetics and blood



multiple sclerosis



(302-304-306)

Hot Topic 4: Remyelination General Epigenome-wide studies: what can we learn from

them?

P Casaccia HT4.1


(302-304-306)

Hot Topic 4: Remyelination General Remyelination in the adult central nervous

system: mechanisms and perspectives

C Lubetzki HT4.2

16:15 - 17:00 Grand Ballroom Hot Topic 5: Inflammation and

neurodegeneration

General Fluorosamine that targets scar components is a

novel therapeutic that promotes myelin

regeneration and reduces inflammation in

demyelination models

M Keough, J Rogers, P Zhang, S Jensen, E

Stephenson, J Plemel, M Hurlbert, C-C Ling, VW

Yong

HT4.3

16:15 - 17:00 Auditorium Hot Topic 6: Society and MS General Neuro-axonal damage in MS may be mediated by

interaction of innate immunity and anti-axonal

antibodies

JD Black, MS Freedman HT5.3

16:15 - 17:00 Hall C Poster Session 2 General Patients as partners in clinical research - Does

the Internet harm or help?

P Wicks HT6.2


Symposium


and Practice


●18:30 - 19:30 Small Ballroom Satellite Symposium Satellite

Symposium



sclerosis?

AbbVie - - - - -

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Exhibit 34: Saturday, September 13, 2014 Saturday - September 13, 2014

Key? Time Room Type Title Authors ID


(302-304-306)


Symposium



Roche - - - - -

●08:30 - 10:00 Auditorium Late Breaking News RPC1063 Phase 2 results of the RADIANCE trial: a





Frohna, K Selmaj

LB1.1

08:30 - 10:00 Auditorium Late Breaking News General The Genomic map of multiple sclerosis: over 45

novel susceptibility variants and translation of

genetics to biology

P De Jager, International MS Genetics

Consortium

LB1.4

10:30 - 12:00 Auditorium Plenary Session 2 General ACTRIMS-ECTRIMS Clinical Research Highlights Speaker: Ellen Mowry PL2.2

10:30 - 12:00 Auditorium Plenary Session 2 General ACTRIMS-ECTRIMS Basic Research Highlights Speaker: Finn Sellebjerg PL2.3

10:00 - 10:30 Outside Hall C Late Breaking News Posters Tecfidera DMF protects neural stem/progenitor cells and

differentiated neurons from oxidative damage

through regulating anti-oxidative stress genes

S Chuikov, S Taitano, Q Wu, Y Mao-Draayer LBP14

10:00 - 10:30 Outside Hall C Late Breaking News Posters GNbAC1 HERV-W envelope protein inhibits

oligodendroglial cell differentiation which can be

abrogated by the neutralizing antibody GNbAC1

D Kremer, M Foerster, T Schichel, P Goettle, H-P

Hartung, H Perron, P Kuery

LBP15

10:00 - 10:30 Outside Hall C Late Breaking News Posters GNbAC1 Follow-up of MS patients from phase IIa clinical

study of GNbAC1 reveals unexpected decrease of

HERV-W endogenous retrovirus genes

expression

R Faucard, A Madeira, N Gehin, T Derfuss, H-P

Hartung, R Du Pasquier, L Kappos, P Lalive, H

Porchet, AB Lang, F Curtin, HJF Perron

LBP16

10:00 - 10:30 Outside Hall C Late Breaking News Posters Betaseron Clinical outcomes in patients with CIS treated with

interferon beta-1b: 11-year follow-up of BENEFIT

L Kappos, G Edan, MS Freedman, X Montalbán,

DH Miller, H-P Hartung, B Hemmer, EJ Fox, F

Barkhof, S Schippling0, A Schulze, D Pleimes, C

Pohl, R Sandbrink, G Suarez, E-M Wicklein, on

behalf of the BENEFIT Study Group

LBP17

10:00 - 10:30 Outside Hall C Late Breaking News Posters Siponomid Impact of siponimod (BAF 312) on CNS

remyelination in a transgenic Xenopus model

A Mannioui, L Azoyan, D Du Pasquier, B Zalc LBP6

10:00 - 10:30 Outside Hall C Late Breaking News Posters General Oligodendroglial cells and signs of remyelination

are present in a subset of early active and inactive

MS lesions despite pronounced axonal damage

E Bahn, C Theodossiou-Wegner, W Brück LBP9

LEGEND

General Novartis

Acorda Receptos

Bayer Sanofi

Biogen Idec Teva

Merck KGaA Xenoport



03 September 2014


Companies Mentioned (Price as of 02-Sep-2014)

AbbVie Inc. (ABBV.N, $55.07) Acorda Therapeut (ACOR.OQ, $32.17) Biogen Idec (BIIB.OQ, $342.68) GENMAB (GEN.CO, Dkr223.5) GlaxoSmithKline plc (GSK.L, 1454.5p) MorphoSys (MORG.DE, €72.46) Novartis (NOVN.VX, SFr85.8) Receptos (RCPT.OQ, $52.75) Sanofi (SASY.PA, €83.76) Teva Pharmaceutical Ind. (TEVA.N, $52.14) XenoPort (XNPT.OQ, $5.18)

Disclosure Appendix

Important Global Disclosures

Ravi Mehrotra PhD, European Pharma Team, Vamil Divan, MD, Koon Ching PhD and Ari Jahja each certify, with respect to the companies or securities that the individual analyzes, that (1) the views expressed in this report accurately reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

The analyst(s) responsible for preparing this research report received Compensation that is based upon various factors including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's investment banking activities

As of December 10, 2012 Analysts’ stock rating are defined as follows:

Outperform (O) : The stock’s total return is expected to outperform the relevant benchmark*over the next 12 months.

Neutral (N) : The stock’s total return is expected to be in line with the relevant benchmark* over the next 12 months.

Underperform (U) : The stock’s total return is expected to underperform the relevant benchmark* over the next 12 months.

*Relevant benchmark by region: As of 10th December 2012, Japanese ratings are based on a stock’s total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. As of 2nd October 2012, U.S. and Canadian as well as European ra tings are based on a stock’s total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attracti ve investment opportunities. For Latin American and non-Japan Asia stocks, ratings are based on a stock’s total return relative to the average total return of the relevant country or regional benchmark; prior to 2nd October 2012 U.S. and Canadian ratings were based on (1) a stock’s absolute total return potential to its current share price and (2) the relative attractiveness of a stock’s total return potential within an analyst’s coverage universe. For Australian and New Zealand stocks, 12 -month rolling yield is incorporated in the absolute total return calculation and a 15% and a 7.5% threshold replace the 10-15% level in the Outperform and Underperform stock rating definitions, respectively. The 15% and 7.5% thresholds replace the +10-15% and -10-15% levels in the Neutral stock rating definition, respectively. Prior to 10th December 2012, Japanese ratings were based on a stock’s total return relative to the average total return of the relevant country or regional benchmark.

Restricted (R) : In certain circumstances, Credit Suisse policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of Credit Suisse's engagement in an investment banking transaction and in certain other circumstances.

Volatility Indicator [V] : A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward.

Analysts’ sector weightings are distinct from analysts’ stock ratings and are based on the analyst’s expectations for the fundamentals and/or valuation of the sector* relative to the group’s historic fundamentals and/or valuation:

Overweight : The analyst’s expectation for the sector’s fundamentals and/or valuation is favorable over the next 12 months.

Market Weight : The analyst’s expectation for the sector’s fundamentals and/or valuation is neutral over the next 12 months.

Underweight : The analyst’s expectation for the sector’s fundamentals and/or valuation is cautious over the next 12 months.

*An analyst’s coverage sector consists of all companies covered by the analyst within the relevant sector. An analyst may cov er multiple sectors.

03 September 2014


Credit Suisse's distribution of stock ratings (and banking clients) is:

Global Ratings Distribution

Rating Versus universe (%) Of which banking clients (%)

Outperform/Buy* 44% (53% banking clients)

Neutral/Hold* 40% (51% banking clients)

Underperform/Sell* 13% (44% banking clients)

Restricted 3%

*For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, an d Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdin gs, and other individual factors.

Credit Suisse’s policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: http://www.csfb.com/research and analytics/disclaimer/managing_conflicts_disclaimer.html

Credit Suisse does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.

Important Regional Disclosures

Singapore recipients should contact Credit Suisse AG, Singapore Branch for any matters arising from this research report.

Restrictions on certain Canadian securities are indicated by the following abbreviations: NVS--Non-Voting shares; RVS--Restricted Voting Shares; SVS--Subordinate Voting Shares.

Individuals receiving this report from a Canadian investment dealer that is not affiliated with Credit Suisse should be advised that this report may not contain regulatory disclosures the non-affiliated Canadian investment dealer would be required to make if this were its own report.

For Credit Suisse Securities (Canada), Inc.'s policies and procedures regarding the dissemination of equity research, please visit http://www.csfb.com/legal_terms/canada_research_policy.shtml.

As of the date of this report, Credit Suisse acts as a market maker or liquidity provider in the equities securities that are the subject of this report.

Principal is not guaranteed in the case of equities because equity prices are variable.

Commission is the commission rate or the amount agreed with a customer when setting up an account or at any time after that.

To the extent this is a report authored in whole or in part by a non-U.S. analyst and is made available in the U.S., the following are important disclosures regarding any non-U.S. analyst contributors: The non-U.S. research analysts listed below (if any) are not registered/qualified as research analysts with FINRA. The non-U.S. research analysts listed below may not be associated persons of CSSU and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Credit Suisse Securities (Europe) Limited ......................................................................................................................... European Pharma Team

For Credit Suisse disclosure information on other companies mentioned in this report, please visit the website at https://rave.credit-suisse.com/disclosures or call +1 (877) 291-2683.

03 September 2014


References in this report to Credit Suisse include all of the subsidiaries and affiliates of Credit Suisse operating under its investment banking division. For more information on our structure, please use the following link: https://www.credit-suisse.com/who_we_are/en/This report may contain material that is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse AG or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CS or its affiliates. The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients of this report as its customers by virtue of their receiving this report. The investments and services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. CS does not advise on the tax consequences of investments and you are advised to contact an independent tax adviser. Please note in particular that the bases and levels of taxation may change. Information and opinions presented in this report have been obtained or derived from sources believed by CS to be reliable, but CS makes no representation as to their accuracy or completeness. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, other communications that are inconsistent with, and reach different conclusions from, the information presented in this report. Those communications reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other communications are brought to the attention of any recipient of this report. Some investments referred to in this report will be offered solely by a single entity and in the case of some investments solely by CS, or an associate of CS or CS may be the only market maker in such investments. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADR's, the values of which are influenced by currency volatility, effectively assume this risk. Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase. Some investments discussed in this report may have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment and, in such circumstances, you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed. This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CS, CS has not reviewed any such site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CS's own website material) is provided solely for your convenience and information and the content of any such website does not in any way form part of this document. Accessing such website or following such link through this report or CS's website shall be at your own risk. This report is issued and distributed in Europe (except Switzerland) by Credit Suisse Securities (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. This report is being distributed in Germany by Credit Suisse Securities (Europe) Limited Niederlassung Frankfurt am Main regulated by the Bundesanstalt fuer Finanzdienstleistungsaufsicht ("BaFin"). This report is being distributed in the United States and Canada by Credit Suisse Securities (USA) LLC; in Switzerland by Credit Suisse AG; in Brazil by Banco de Investimentos Credit Suisse (Brasil) S.A or its affiliates; in Mexico by Banco Credit Suisse (México), S.A. (transactions related to the securities mentioned in this report will only be effected in compliance with applicable regulation); in Japan by Credit Suisse Securities (Japan) Limited, Financial Instruments Firm, Director-General of Kanto Local Finance Bureau (Kinsho) No. 66, a member of Japan Securities Dealers Association, The Financial Futures Association of Japan, Japan Investment Advisers Association, Type II Financial Instruments Firms Association; elsewhere in Asia/ Pacific by whichever of the following is the appropriately authorised entity in the relevant jurisdiction: Credit Suisse (Hong Kong) Limited, Credit Suisse Equities (Australia) Limited, Credit Suisse Securities (Thailand) Limited, regulated by the Office of the Securities and Exchange Commission, Thailand, having registered address at 990 Abdulrahim Place, 27th Floor, Unit 2701, Rama IV Road, Silom, Bangrak, Bangkok 10500, Thailand, Tel. +66 2614 6000, Credit Suisse Securities (Malaysia) Sdn Bhd, Credit Suisse AG, Singapore Branch, Credit Suisse Securities (India) Private Limited (CIN no. U67120MH1996PTC104392) regulated by the Securities and Exchange Board of India (registration Nos. INB230970637; INF230970637; INB010970631; INF010970631), having registered address at 9th Floor, Ceejay House, Dr.A.B. Road, Worli, Mumbai - 18, India, T- +91-22 6777 3777, Credit Suisse Securities (Europe) Limited, Seoul Branch, Credit Suisse AG, Taipei Securities Branch, PT Credit Suisse Securities Indonesia, Credit Suisse Securities (Philippines ) Inc., and elsewhere in the world by the relevant authorised affiliate of the above. Research on Taiwanese securities produced by Credit Suisse AG, Taipei Securities Branch has been prepared by a registered Senior Business Person. Research provided to residents of Malaysia is authorised by the Head of Research for Credit Suisse Securities (Malaysia) Sdn Bhd, to whom they should direct any queries on +603 2723 2020. This report has been prepared and issued for distribution in Singapore to institutional investors, accredited investors and expert investors (each as defined under the Financial Advisers Regulations) only, and is also distributed by Credit Suisse AG, Singapore branch to overseas investors (as defined under the Financial Advisers Regulations). By virtue of your status as an institutional investor, accredited investor, expert investor or overseas investor, Credit Suisse AG, Singapore branch is exempted from complying with certain compliance requirements under the Financial Advisers Act, Chapter 110 of Singapore (the "FAA"), the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder, in respect of any financial advisory service which Credit Suisse AG, Singapore branch may provide to you. This research may not conform to Canadian disclosure requirements. In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. U.S. customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse Securities (USA) LLC in the U.S. Please note that this research was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority or in respect of which the protections of the Prudential Regulation Authority and Financial Conduct Authority for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report. CS may provide various services to US municipal entities or obligated persons ("municipalities"), including suggesting individual transactions or trades and entering into such transactions. Any services CS provides to municipalities are not viewed as "advice" within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. CS is providing any such services and related information solely on an arm's length basis and not as an advisor or fiduciary to the municipality. In connection with the provision of the any such services, there is no agreement, direct or indirect, between any municipality (including the officials, management, employees or agents thereof) and CS for CS to provide advice to the municipality. Municipalities should consult with their financial, accounting and legal advisors regarding any such services provided by CS. In addition, CS is not acting for direct or indirect compensation to solicit the municipality on behalf of an unaffiliated broker, dealer, municipal securities dealer, municipal advisor, or investment adviser for the purpose of obtaining or retaining an engagement by the municipality for or in connection with Municipal Financial Products, the issuance of municipal securities, or of an investment adviser to provide investment advisory services to or on behalf of the municipality. If this report is being distributed by a financial institution other than Credit Suisse AG, or its affiliates, that financial institution is solely responsible for distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this report or require further information. This report does not constitute investment advice by Credit Suisse to the clients of the distributing financial institution, and neither Credit Suisse AG, its affiliates, and their respective officers, directors and employees accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content. Principal is not guaranteed. Commission is the commission rate or the amount agreed with a customer when setting up an account or at any time after that.

Copyright © 2014 CREDIT SUISSE AG and/or its affiliates. All rights reserved.

Investment principal on bonds can be eroded depending on sale price or market price. In addition, there are bonds on which investment principal can be eroded due to changes in redemption amounts. Care is required when investing in such instruments. When you purchase non-listed Japanese fixed income securities (Japanese government bonds, Japanese municipal bonds, Japanese government guaranteed bonds, Japanese corporate bonds) from CS as a seller, you will be requested to pay the purchase price only.

ACTRIMS-ECTRIMS Planner.doc

https://www.credit-suisse.com/who_we_are/en/

Documents

ACTRIMS-ECTRIMS 2014